Publications 2016-20192019-06-05T14:40:13+00:00

PUBLICATIONS LIST

BTD–  subsidized members only 2018-2019 (53)


  1. Cavallone L1, Aldamry M2, Lafleur J1, Lan C1, Gonzalez Ginestet P3, Alirezaie N4, Ferrario C1, Aguilar-Mahecha A1, Basik M5. A Study of Pre-Analytical Variables and Optimization of Extraction Method for Circulating Tumor DNA Measurements by Digital Droplet PCR. Cancer Epidemiol Biomarkers Prev. 2019 May;28(5):909-916. doi: 10.1158/1055-9965.EPI-18-0586. Epub 2019 Mar 1.
  2. Furrer, D., Jacob, S., Michaud, A., Provencher, L., Lemieux, J., et Diorio, C. Association between tobacco and alcohol consumption, HER2 polymorphisms and response to trastuzumab in HER2-positive breast cancer patients. Clin Breast Cancer. 2018 Aug;18(4):e687-e694. doi: 10.1016/j.clbc.2017.11.012. Epub 2017 Nov 23.
  3. Poirier, É., Desbiens, C., Poirier, B., Boudreau, D., Jacob, S., Lemieux, J., Doyle, C., Diorio, C., Hogue, J.C., et Provencher, L. Characteristics and long-term survival of patients diagnosed with pure tubular carcinoma of the breast. J Surg Oncol. 2018 May;117(6):1137-1143.
  4. Hanna, M., Dumas, I., Orain, M., Jacob, S., Têtu, B., et Diorio, C. Association between physical activity and the expression of mediators of inflammation in normal breast tissue among premenopausal and postmenopausal women. Cytokine. 2018 Feb;102:151-160.
  5. Nabi, H., et Diorio, C. Body mass index and clinical outcomes in trastuzumab-treated metastatic breast cancer patients: An alternative explanation for the lack of association. Breast. 2018 Jun;39:150-151. doi: 10.1016/j.breast.2018.02.030. Epub 2018 Mar 9.
  6. Nabi, H., Provencher, L., et Diorio, C. Re: Smoking, Sex, and Non-Small Cell Lung Cancer: Steroid hormone Receptors in Tumor Tissue. J Natl Cancer Inst. 2018 Dec 1;110(12):1422-1423.
  7. Poirier, É., Desbiens, C., Poirier, B., Boudreau, D., Jacob, S., Lemieux, J., Doyle, C., Diorio, C., Hogue, J.C., et Provencher, L. In response to: Long-term survival of patients diagnosed with pure tubular carcinoma of the breast might be affected by increased co-morbidities. J Surg Oncol. 2018 Jun;117(7):1615. doi: 10.1002/jso.24982. Epub 2018 Mar 30.
  8. Nabi, H., Guertin, J.R., Talbot, D., et Diorio, C. Body-mass index and metastatic melanoma outcomes. Lancet Oncol. 2018 May;19(5):e226.
  9. Slim, F.A., Ouellette, G., Ennour-Idrissi, K., Jacob, S., Diorio, C., et Durocher, F. An isoform of AIF1 involved in breast cancer. Cancer Cell Int. 2018 Oct 22;18:167. doi: 10.1186/s12935-018-0663-3. eCollection 2018.
  10. Kothari, C., Ouellette, G., Labrie, Y., Jacob, S., Diorio, C., et Durocher, F. Identification of a gene signature for different stages of breast cancer development that could be used for early diagnosis and specific therapy.Oncotarget. 2018 Dec 21;9(100):37407-37420. doi: 10.18632/oncotarget.26448. eCollection 2018 Dec 21.
  11. Pejovic T, McCluggage WG, Krieg AJ, Xu F, Lee DM, Witkowski L, Foulkes WD. The dilemma of early preventive oophorectomy in familial small cell carcinoma of the ovary of hypercalcemic type. J Clin Oncol. 2019 Feb 20;37(6):461-470. doi: 10.1200/JCO.18.00474. Epub 2019 Jan 4.
  12. Kotsopoulos J, Lubinski J, Lynch HT, Tung N, Armel S, Senter L, Singer CF, Fruscio R, Couch F, Weitzel JN, Karlan B, Foulkes WD, Moller P, Eisen A, Ainsworth P, Neuhausen SL, Olopade O, Sun P, Gronwald J, Narod SA And Hereditary Breast Cancer Clinical Study Group. Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2019 Feb 12. doi: 10.1007/s10549-019-05162-7. [Epub ahead of print]
  13. Grolleman JE, de Voer RM, Elsayed FA, Nielsen M, Weren RDA, Palles C, Ligtenberg MJL, Vos JR, Ten Broeke SW, de Miranda NFCC, Kuiper RA, Kamping EJ, Jansen EAM, Vink-Börger ME, Popp I, Lang A, Spier I, Hüneburg R, James PA, Li N, Staninova M, Lindsay H, Cockburn D, Spasic-Boskovic O, Clendenning M, Sweet K, Capellá G, Sjursen W, Høberg-Vetti H, Jongmans MC, Neveling K, Geurts van Kessel A, Morreau H, Hes FJ, Sijmons RH, Schackert HK, Ruiz-Ponte C, Dymerska D, Lubinski J, Rivera B, Foulkes WD, Tomlinson IP, Valle L, Buchanan DD, Kenwrick S, Adlard J, Dimovski AJ, Campbell IG, Aretz S, Schindler D, van Wezel T, Hoogerbrugge N, Kuiper RP. Mutational Signature Analysis Reveals NTHL1 Deficiency to Cause a Multi-tumor Phenotype. Cancer Cell. 2019 Feb 11;35(2):256-266.e5. doi: 10.1016/j.ccell.2018.12.011.
  14. Xue Y, Meehan B, Macdonald E, Venneti S, Wang X-Q, Witkowski L, Jelinic P, Kong T, Martinez D, Morin G, Firlit M, Abedini A, Johnson R, Cencic R, Patibandla J, Chen H, Papadakis A, Auguste A, de Rink I, Kerkhoven R, Bertos N, Gotlieb W, Clarke B, Leary A, Witcher M, Guiot M-C, Pelletier J, Dostie J, Park M, Judkins A, Hass R, Levine D, Rak J, Vanderhyden B, Foulkes W, and Huang S. CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary. Nat Commun. 2019 Feb 4;10(1):558. doi: 10.1038/s41467-018-06958-9.
  15. Metcalfe K, Lynch HT, Foulkes WD, Tung N, Olopade OI, Eisen A, Lerner-Ellis J, Snyder C, Kim SJ, Sun P, Narod SA. Oestrogen receptor status and survival in women with BRCA2-associated breast cancer. Br J Cancer. 2019 Feb;120(4):398-403. doi: 10.1038/s41416-019-0376-y. Epub 2019 Feb 6.
  16. McCluggage WG, Chong AS, Attygalle AD, Clarke BA, Chapman W, Rivera B, Foulkes WD. Expanding the morphological spectrum of ovarian microcystic stromal tumour. Histopathology. 2019 Feb;74(3):443-451. doi: 10.1111/his.13755. Epub 2018 Dec 5.
  17. Cline MS, Liao RG, Parsons MT, Paten B, Alquaddoomi F, Antoniou A, Baxter S, Brody L, Cook-Deegan R, Coffin A, Couch FJ, Craft B, Currie R, Dlott CC, Dolman L, den Dunnen JT, Dyke SOM, Domchek SM, Easton D, Fischmann Z, Foulkes WD, Garber J, , Goldgar D, Goldman MJ, Goodhand P, Harrison S, Haussler D, Kato K, Knoppers B, Markello C, Nussbaum R, Offit K, Plon SE, Rashbass J, Rehm HL, Robson M, Rubinstein WS, Stoppa-Lyonnet D, Tavtigian S, Thorogood A, Zhang C, Zimmermann M; BRCA Challenge Authors, Burn J Chanock S, Rätsch G, Spurdle AB. BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2. PLoS Genet. 2018 Dec 26;14(12):e1007752. doi: 10.1371/journal.pgen.1007752. eCollection 2018 Dec.
  18. Roussel L, Landekic M, Golizeh M, Gavino C, Zhong MC, Chen J, Faubert D, Blanchet-Cohen A, Dansereau L, Parent MA, Marin S, Luo J, Le C, Ford BR, Langelier M, King IL, Divangahi M, Foulkes WD, Veillette A, Vinh DC. Loss of human ICOSL results in combined immunodeficiency. J Exp Med. 2018 Dec 3;215(12):3151-3164. doi: 10.1084/jem.20180668.
  19. Fahiminiya S, Sabbaghian N, Albrecht S, Nadaf J, Callegaro-Filho D, Foulkes WD. Ovarian small cell carcinoma in one of a pair of monozygous twins. Fam Cancer. 2019 Apr;18(2):161-163. doi: 10.1007/s10689-018-0108-0.
  20. Kotsopoulos J, Gronwald J, Lynch HT, Eisen A, Neuhausen SL, Tung N, Ainsworth P, Weitzel JN, Pal T, Foulkes WD, Eng C, Singer CF, Senter L, Sun P, Lubinski J, Narod SA, Hereditary Breast Cancer Clinical Study Group. Age at first full-term birth and breast cancer risk in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2018 Sep;171(2):421-426. doi: 10.1007/s10549-018-4822-y. Epub 2018 May 17.
  21. McCuaig JM, Stockley TL, Shaw P, Fung-Kee-Fung M, Altman AD, Bentley J, Bernardini MQ, Cormier B, Hirte H, Kieser K, MacMillan A, Meschino WS, Panabaker K, Perrier R, Provencher D, Schrader KA, Serfas K, Tomiak E, Wong N, Young SS, Gotlieb WH, Hoskins P, Kim RH; BRCA TtoT Community of Practice. Evolution of genetic assessment for BRCA-associated gynaecologic malignancies: a Canadian multisociety roadmap. J Med Genet. 2018 Sep;55(9):571-577. doi: 10.1136/jmedgenet-2018-105472. Epub 2018 Jul 24.
  22. Kotsopoulos J, Gronwald J, Karlan BY, Huzarski T, Tung N, Moller P, Armel S, Lynch HT, Senter L, Eisen A, Singer CF, Foulkes WD, Jacobson MR, Sun P, Lubinski J, Narod SA; Hereditary Breast Cancer Clinical Study Group. Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers. JAMA Oncol. 2018 Aug 1;4(8):1059-1065.
  23. Kotsopoulos J, Gronwald J, Karlan B, Rosen B, Huzarski T, Moller P, Lynch HT, Singer CF, Senter L, Neuhausen SL, Tung N, Eisen A, Foulkes WD, Ainsworth P, Sun P, Lubinski J, Narod SA; Hereditary Ovarian Cancer Clinical Study Group. Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation. Gynecol Oncol. 2018 Jul;150(1):85-91. doi: 10.1016/j.ygyno.2018.05.011. Epub 2018 May 21.
  24. Kim SJ, Huzarski T, Gronwald J, Singer CF, MØller P, Lynch HT, Armel S, Karlan BY, Foulkes WD, Neuhausen SL, Senter L, Eisen A, Eng C, Panchal S, Pal T, Olopade O, Zakalik D, Lubinski J, Narod SA, Kotsopoulos J; Hereditary Breast Cancer Clinical Study Group. Prospective evaluation of body size and breast cancer risk among BRCA1 and BRCA2 mutation carriers. Int J Epidemiol. 2018 Mar 13. doi: 10.1093/ije/dyy039. [Epub ahead of print]
  25. Lammert J, Lubinski J, Gronwald J, Huzarski T, Armel S, Eisen A, Meschino WS, Lynch HT, Snyder C, Eng C, Olopade OI, Ginsburg O, Foulkes WD, Elser C, Cohen SA, Kiechle M, Narod SA, Kotsopoulos J. Physical activity during adolescence and young adulthood and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2018 Jun;169(3):561-571. doi: 10.1007/s10549-018-4694-1. Epub 2018 Feb 5.
  26. Ko KP, Kim SJ, Huzarski T, Gronwald J, Lubinski J, Lynch HT, Armel S, Park SK, Karlan B, Singer CF, Neuhausen SL, Narod SA, Kotsopoulos J; Hereditary Breast Cancer Clinical Study Group. The association between smoking and cancer incidence in BRCA1 and BRCA2 mutation carriers. Int J Cancer. 2018 Jun 1;142(11):2263-2272. doi: 10.1002/ijc.31257. Epub 2018 Jan 25.
  27. Metcalfe KA, Lubinski J, Gronwald J, Huzarski T, McCuaig J, Lynch HT, Karlan B, Foulkes WD, Singer CF, Neuhausen SL, Senter L, Eisen A, Sun P, Narod SA; and the Hereditary Breast Cancer Clinical Study Group. The risk of breast cancer in BRCA1 and BRCA2 mutation carriers without a first-degree relative with breast cancer. Clin Genet. 2018 May;93(5):1063-1068. doi: 10.1111/cge.13191. Epub 2018 Mar 25.
  28. Leung L, Grundy A, Siemiatycki J, Arseneau J, Gilbert L, Gotlieb WH, Provencher DM, Aronson KJ, Koushik A. Shift Work Patterns, Chronotype, and Epithelial Ovarian Cancer Risk. Cancer Epidemiol Biomarkers Prev. 2019 Mar 6. pii: cebp.1112.2018. doi: 10.1158/1055-9965.EPI-18-1112
  29. Xue Y, Meehan B, Macdonald E, Venneti S, Wang XQD, Witkowski L, Jelinic P, Kong T, Martinez D, Morin G, Firlit M, Abedini A, Johnson RM, Cencic R, Patibandla J, Chen H, Papadakis AI, Auguste A, de Rink I, Kerkhoven RM, Bertos N, Gotlieb WH, Clarke BA, Leary A, Witcher M, Guiot MC, Pelletier J, Dostie J, Park M, Judkins AR, Hass R, Levine DA, Rak J, Vanderhyden B, Foulkes WD, Huang S.Nat Commun. CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary. 2019 Feb 4;10(1):558. doi: 10.1038/s41467-018-06958-9.
  30. Baloch T, López-Ozuna VM, Wang Q, Matanis E, Kessous R, Kogan L, Yasmeen A, Gotlieb WH. Sequential therapeutic targeting of ovarian Cancer harboring dysfunctional BRCA1. BMC Cancer. 2019 Jan 10;19(1):44. doi: 10.1186/s12885-018-5250-4
  31. Matanes E, Abitbol J, Kessous R, Kogan L, Octeau D, Lau S, Salvador S, Gotlieb WH. Oncologic and Surgical Outcomes of Robotic Versus Open Radical Hysterectomy for Cervical Cancer. J Obstet Gynaecol Can. 2019 Apr;41(4):450-458. doi: 10.1016/j.jogc.2018.09.013. Epub 2018 Dec 7.
  32. Laskov I, Kessous R, Abitbol J, Kogan L, Badeghiesh A, Tagalakis V, Cohen S, Salvador S, Lau S, Gotlieb WH; Risk of Thromboembolic Disease With Cost Estimates in Patients Undergoing Robotic Assisted Surgery for Endometrial Cancer and Review of the Literature. SOGC Communities of Practice.J Obstet Gynaecol Can. 2018 Dec;40(12):1571-1579. doi: 10.1016/j.jogc.2018.04.003. Epub 2018 Sep 24.
  33. Piedimonte S, Czuzoj-Shulman N, Gotlieb W, Abenhaim HA. Robotic Radical Hysterectomy for Cervical Cancer: A Population-Based Study of Adoption and Immediate Postoperative Outcomes in the United States. J Minim Invasive Gynecol. 2019 Mar – Apr;26(3):551-557. doi: 10.1016/j.jmig.2018.08.012. Epub 2018 Sep 5.
  34. Kogan L, Octeau D, Amajoud Z, Abitbol J, Laskov I, Ferenczy A, Pelmus M, Eisenberg N, Kessous R, Lau S, Yasmeen A, Gotlieb WH, Salvador S. Impact of lower uterine segment involvement in type II endometrial cancer and the unique mutational profile of serous tumors. Gynecol Oncol Rep. 2018 Mar 19;24:43-47. doi: 10.1016/j.gore.2018.03.004. eCollection 2018 May.
  35. Le Page C, Rahimi K, Köbel M, Tonin PN, Meunier L, Portelance L, Bernard M, Nelson BH, Bernardini MQ, Bartlett JMS, Bachvarov D, Gotlieb WH, Gilks B, McAlpine JN, Nachtigal MW, Piché A, Watson PH, Vanderhyden B, Huntsman DG, Provencher DM, Mes-Masson AM. Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers. BMC Cancer. 2018 Mar 27;18(1):347.
  36. How JA, O’Farrell P, Amajoud Z, Lau S, Salvador S, How E, Gotlieb WH. Sentinel lymph node mapping in endometrial cancer: a systematic review and meta-analysis.
    Minerva Ginecol. 2018 Apr;70(2):194-214. doi: 10.23736/S0026-4784.17.04179-X. Epub 2017 Nov 28. Review.
  37. Monette A1,2,3, Bergeron D4, Ben Amor A5, Meunier L6,7, Caron C6,7, Mes-Masson AM6,7,4, Kchir N8, Hamzaoui K5,9, Jurisica I10,11, Lapointe R. Immune-enrichment of non-small cell lung cancer baseline biopsies for multiplex profiling define prognostic immune checkpoint combinations for patient stratification. J Immunother Cancer. 2019 Mar 28;7(1):86. doi: 10.1186/s40425-019-0544-x.
  38. Monette A, Morou A, Al-Banna NA, Rousseau L, Lattouf JB, Rahmati S, Tokar T, Routy JP, Cailhier JF, Kaufmann DE, Jurisica I, Lapointe R. Failed immune responses across multiple pathologies share pan-tumor and circulating lymphocytic targets. J Clin Invest. 2019 Mar 26;130. pii: 125301. doi: 10.1172/JCI125301.
  39. Khashayar Esfahani, Najwa Buhlaiga, Paméla Thébault, Réjean Lapointe, Nathalie Johnson, Wilson H. Miller Jr. Alemtuzumab for immune-related myocarditis from PD-1 therapy. New Englend Journal of Medicine (correspondence)
  40. Le Page C, Köbel M, Meunier L, Provencher DM, Mes-Masson AM, Rahimi K. A CŒUR cohort study of SATB2 expression and its prognostic value in ovarian endometrioid carcinoma. J Pathol Clin Res. 2019 Mar 28. doi: 10.1002/cjp2.131. [Epub ahead of print]
  41. Simeone K, Guay-Lord R, Lateef MA, Péant B, Kendall-Dupont J, Orimoto AM, Carmona E, Provencher D, Saad F, Gervais T, Mes-Masson AM. Paraffin-embedding lithography and micro-dissected tissue micro-arrays: tools for biological and pharmacological analysis of ex vivo solid tumors. Lab Chip. 2019 Feb 12;19(4):693-705.
  42. Le Page C, Rahimi K, Mes-Masson AM, Köbel M. Prognostic value of progesterone receptor expression in tubo-ovarian high-grade serous carcinoma of the CŒUR cohort. Histopathology. 2019 Mar;74(4):663-666.
  43. Bélanger F, Fortier E, Dubé M, Lemay JF, Buisson R, Masson JY, Elsherbiny A, Costantino S, Carmona E, Mes-Masson AM, Wurtele H, Drobetsky E. Replication Protein A Availability during DNA Replication Stress Is a Major Determinant of Cisplatin Resistance in Ovarian Cancer Cells. Cancer Res. 2018 Oct 1;78(19):5561-5573.
  44. St-Georges-Robillard A, Masse M, Cahuzac M, Strupler M, Patra B, Orimoto AM, Kendall-Dupont J, Péant B, Mes-Masson AM, Leblond F, Gervais T. Fluorescence hyperspectral imaging for live monitoring of multiple spheroids in microfluidic chips. 2018 Aug 6;143(16):3829-3840.
  45. Goyette, M. A., Duhamel, S., Aubert, L., Pelletier, A., Savage, P., Thibault, M. P., Johnson, R. M., Carmeliet, P., Basik, M., Gaboury, L., Muller, W. J., Park, M., Roux, P. P., Gratton, J. P., & Cote, J. F. The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression. Cell Rep. 2018 May 1;23(5):1476-1490. doi: 10.1016/j.celrep.2018.04.019.
  46. Bernier, C., Soliman, A., Gravel, M., Dankner, M., Savage, P., Petrecca, K.,Park, M., Siegel, P. M., Shore, G. C., & Roulston, A. DZ-2384 has a superior preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapy. Anticancer Drugs. 2018 Sep;29(8):774-785.
  47. Hirukawa, A., Smith, H. W., Zuo, D., Dufour, C. R., Savage, P., Bertos, N., Johnson, R. M., Bui, T., Bourque, G., Basik, M., Giguere, V., Park, M., & Muller, W. J. Targeting EZH2 reactivates a breast cancer subtype-specific anti-metastatic transcriptional program. Nat Commun. 2018 Jun 29;9(1):2547. doi: 10.1038/s41467-018-04864-8.
  48. Robichaud, N., Hsu, B. E., Istomine, R., Alvarez, F., Blagih, J., Ma, E. H., Morales, S. V., Dai, D. L., Li, G., Souleimanova, M., Guo, Q., Del Rincon, S. V., Miller, W. H., Jr., Ramon, Y. C. S.,Park, M., Jones, R. G., Piccirillo, C. A., Siegel, P. M., & Sonenberg, N. Translational control in the tumor microenvironment promotes lung metastasis: Phosphorylation of eIF4E in neutrophils. Proc Natl Acad Sci U S A. 2018 Mar 6;115(10):E2202-E2209.
  49. Gruosso, T., Gigoux, M., Manem, V. S. K., Bertos, N., Zuo, D., Perlitch, I., Saleh, S. M. I., Zhao, H., Souleimanova, M., Johnson, R. M., Monette, A., Ramos, V. M., Hallett, M. T., Stagg, J., Lapointe, R., Omeroglu, A., Meterissian, S., Buisseret, L., Van den Eyden, G., Salgado, R., Guiot, M. C., Haibe-Kains, B., & Park, M. Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers. J Clin Invest. 2019 Apr 1;129(4):1785-1800. doi: 10.1172/JCI96313. Epub 2019 Mar 18.
  50. Murali, B., Ren, Q., Luo, X., Faget, D. V., Wang, C., Johnson, R. M., Gruosso, T., Flanagan, K. C., Fu, Y., Leahy, K. M., Alspach, E., Su, X., Ross, M. H., Burnette, B., Weilbaecher, K. N., Park, M., Mbalaviele, G., Monahan, J., & Stewart, S. A. Inhibition of the stromal p38MAPK/MK2 pathway limits breast cancer metastases and chemotherapy-induced bone loss. Cancer Res. 2018 Oct 1;78(19):5618-5630. doi: 10.1158/0008-5472.CAN-18-0234. Epub 2018 Aug 9.
  51. Li, X., Gruosso, T., Zuo, D., Omeroglu, A., Meterissian, S., Guiot, M. C., Salazar, A., Park, M., & Levine, H. Infiltration of CD8(+) T cells into tumor cell clusters in triple-negative breast cancer. Proc Natl Acad Sci U S A. 2019 Feb 26;116(9):3678-3687. doi: 10.1073/pnas.1817652116. Epub 2019 Feb 7.
  52. Lane D1, Matte I1, Garde-Granger P2, Bessette P3, Piché A Serum CA125 and ascites leptin level ratio predicts baseline clinical resistance to first-line platinum-based treatment and poor prognosis in patients with high grade serous ovarian cancer. Am J Cancer Res. 2019 Jan 1;9(1):160-170.
  53. Lane D1, Matte I1, Garde-Granger P2, Bessette P3, Piché A Ascites IL-10 promotes ovarian cancer cell migration. Cancer Microenviron. 2018 Dec;11(2-3):115-124. doi: 10.1007/s12307-018-0215-3.

TE 2018-2019 (42)


  1. Findlay S, Heath J, Luo VM, Malina A, Morin T, Coulombe Y, Djerir B, Li Z, Samiei A, Cheyou ES, Karam M, Bagci H, Rahat D, Grapton D, Lavoie EG, Dove C, Khaled H, Kuasne H, Mann KK, Klein KO, Greenwood CM, Tabach Y, Park M, Côté JF, Masson JY, Maréchal A, Orthwein A. SHLD2 co-operates with REV7 to coordinate DNA double-strand break repair pathway choice. EMBO J. 37(18): e100158.
  2. Vadnais C, Chen R, Fraszczak J, Yu Z, Boulais J, Pinder J, Frank D, Khandanpour C, Hebert J, Dellaire G, Cote JF, Richard S, Orthwein A, Drobetsky E, Moroy T. GFI1 is required for efficient DNA Repair by regulating PRMT1 dependent methylation of MRE11 and 53BP1. Nat Commun. 2018;9(1):1418.
  3. Harutyunyan A, Krug B, Chen H, Papillon-Cavanagh S, Zeinieh M, De Jay N, Deshmukh S, Chen CCL, Belle J, Mikael LG, Marchione DM, Li R, Nikbakht H, Hu B, Cagnone G, Cheung WA, Mohammadnia A, Bechet D, Faury D, McConechy MK, Pathania M, Jain SU, Ellezam B, Weil AG, Montpetit A, Salomoni P, Pastinen T, Lu C, Lewis PW, Garcia BA, Kleinman CL, Jabado N, Majewski J. H3K27M induces defective chromatin spread of PRC2-mediated repressive H3K27me2/me3 and is essential for glioma tumorigenesis. Nature Communications. 2019;10:1262.
  4. Gomes CC, Gayden T, Bajic A, Harraz OF, Pratt J, Nikbakht H, Bareke E, Diniz MG, Henriques Castro W, St-Onge P, Sinnett D, Han H, Rivera B, Mikael LG, De Jay N, Kleinman CL, Valera ET, Bassenden AV, Berghuis AM, Majewski J, Nelson MT, Gomez RS, Jabado N. TRPV4 and KRAS and FGFR1 gain-of-function mutations drive giant cell lesions of the jaw. Nature Communications. 2018;9(1):4572.
  5. Vairy S, Jouan L, Bilodeau M, Dormoy-Raclet V, Gendron P, Couture F, Léveillé F, Tihy F, Lemyre E, Bouron-Dal Soglio D, Jabado N, Kleinman CL, Marzouki M, Cellot S. Novel PDE10A-BRAF fusion with concomitant NF1 mutation identified in an undifferentiated sarcoma of infancy with sustained response to Trametinib. JCO Precision Oncology. 2018;2:1-13.
  6. Calabretta S, Vogel G, Yu Z, Choquet K, Darbelli L, Nicholson TB, Kleinman CL, Richard S. Loss of PRMT5 promotes PDGFRα degradation during oligodendrocyte differentiation and myelination. Developmental Cell. 2018;46(4):426-440.
  7. Ha JR, Ahn R, Smith HW, Sabourin V, Hébert S, Cepeda Cañedo E, Im YK, Kleinman CL, Muller WJ, Ursini-Siegel J. Integration of distinct ShcA signaling complexes promotes breast tumor growth and tyrosine kinase inhibitor resistance. Molecular Cancer Research. 2018;16(5):894-908.
  8. Banerji U, Dean EJ, Pérez-Fidalgo JA, Batist G, Bedard PL, You B, Westin SN, Kabos P, Garrett MD, Tall M, Ambrose H, Barrett JC, Carr TH, Cheung SYA, Corcoran C, Cullberg M, Davies BR, de Bruin EC, Elvin P, Foxley A, Lawrence P, Lindemann JPO, Maudsley R, Pass M, Rowlands V, Rugman P, Schiavon G, Yates J, Schellens JHM. A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers. Clin Cancer Res. 2018;24(9):2050-2059. doi: 10.1158/1078-0432.CCR-17-2260.
  9. Alcaide M, Cheung M, Bushell K, Arthur SE, Wong HL, Karasinska J, Renouf D, Schaeffer DF, McNamara S, Tertre MCD, Batist G, Kennecke HF, Karsan A, Morin RD. A Novel Multiplex Droplet Digital PCR Assay to Identify and Quantify KRAS Mutations in Clinical Specimens.Mol Diagn. 2019;21(2):214-227. doi: 10.1016/j.jmoldx.2018.09.007.
  10. Im YK, Najyb O, Gravel SP, McGuirk S, Ahn R, Avizonis DZ, Chénard V, Valerie Sabourin V, Hudson J, Pawson T, Topisirovic I, Pollak M, St-Pierre J, Ursini-Siegel J. Interplay between ShcA signaling and PGC-1α triggers targetable metabolic vulnerabilities in breast cancer. Cancer Res. 2018;78(17):4826-4838. doi: 10.1158/0008-5472.CAN-17-3696.
  11. Liu S, Hausmann S, Carlson SM, Fuentes ME, Francis JW, Pillai R, Lofgren SM, Hulea L, Tandoc K, Lu J, Li A, Nguyen ND, Caporicci M, Kim MP, Maitra A, Wang H, Wistuba II, Porco JA Jr, Bassik MC, Elias JE, Song J, Topisirovic I, Van Rechem C, Mazur PK, Gozani O. METTL13 Methylation of eEF1A Increases Translational Output to Promote Tumorigenesis. Cell. 2019;176(3):491-504.e21. doi: 10.1016/j.cell.2018.11.038.
  12. Zahreddine HA, Culjkovic-Kraljacic B, Gasiorek J, Duchaine J, Borden KLB. Glioma associated protein 1 (GLI1)-inducible glucuronidation targets a broad spectrum of drugs. ACS Chemical Biology. 2019;14(3):348-355.
  13. Osborne MJ, Coutinho de Oliveira L, Volpon L, Zahreddine HA, Borden KLB. Overcoming Drug Resistance through the Development of Selective Inhibitors of UDP-Glucuronosyltransferase Enzymes. Journal of Molecular Biology. 2019;431(2):258-272.
  14. Urtishak KA*, Wang LS, Culjkovic-Kraljacic B, Davenport JW, Porazzi P, Vincent TL, Teachey DT, Tasian SK, Moore JS, Seif AE, Jin S, Barrett JS, Robinson BW, Chen IL, Harvey RC, Carroll MP, Carroll AJ, Heerema NA, Devidas M, Dreyer ZE, Hilden JM, Hunger SP, Willman CL, Borden KLB*, Felix CA* (cosenior).Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia. Oncogene. 2019;38(13):2241-2262.
  15. Ngeow KC, Friedrichsen HJ, Li L, Zeng Z, Andrews S, Volpon L, Brunsdon H, Berridge G, Picaud S, Fischer R, Lisle R, Knapp S, Filippakopoulos P, Knowles H, Steingrímsson E, Borden KLB, Patton EE, Goding CR. BRAF/MAPK and GSK3 signalling converge to control MITF nuclear export. Proceedings of the National Academy of Sciences. 2018;115(37):E8668E8677.
  16. Zaja F, Salvi F, Rossi M, Sabattini E, Evangelista A, Ciccone G, Angelucci E, Gaidano G, Zanni M, Ladetto M, Chiappella A, Vitolo U, Zinzani PL, Califano C, Tucci A, Patti C, Pileri SA, Lenti V, Piccaluga PP, Cavallo F, Volpetti S, Perali G, Assouline S, Mann KK , Morin R, Alcaide M, Bushell K, Fanin R, Levis A. Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi. Leuk Lymphoma. 2018;59(12):2904-2910.
  17. Goyette MA, Duhamel S, Aubert L, Pelletier A, Savage P, Thibault MP, Johnson RM, Carmeliet P, Basik M, Gaboury L, Muller WJ, Park M, Roux PP, Gratton JP, Côté JF. The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression. Cell Rep. 2018;23(5):1476-1490. doi:10.1016/j.celrep.2018.04.019. PMID:29719259
  18. Marques M, Jangal M, Wang LC, Kazanets A, da Silva SD, Zhao T, Lovato A, Yu H, Jie S, del Rincon S, Mackey J, Damaraju S, Alaoui-Jamali M and Witcher M. Oncogenic activity of poly (ADP-ribose) glycohydrolase. 2019;38:2177-2191.
  19. Silva SD, Xu B, Maschietto M, Marchi FA, Alkailani MI, Bijian K, Xiao D, Alaoui-Jamali MA. TRAF2 cooperates with focal adhesion signaling to regulate cancer cell susceptibility to anoikis. Mol Cancer Ther. 2019;18(1):139-146.
  20. Li L, Guturi KKN, Gautreau B, Patel PS, Saad A, Morii M, Mateo F, Palomero L, Barbour H, Gomez A, Ng D, Kotlyar M, Pastrello C, Jackson HW, Khokha R, Jurisica I, Affar EB, Raught B, Sanchez O, Alaoui-Jamali M, Pujana MA, Hakem A, Hakem R. Ubiquitin ligase RNF8 suppresses Notch signaling to regulate mammary development and tumorigenesis.J Clin Invest. 2018;128(10):4525-4542.
  21. Bijian K, Kaldre D, Wang TT, Su J, Bouttier M, Boucher A, Alaoui-Jamali M, White JH, Gleason JL. Efficacy of hybrid vitamin D receptor agonist/histone deacetylase inhibitors in vitamin D-resistant triple-negative 4T1 breast cancer. J Steroid Biochem Mol Biol. 2018;177:135-139.
  22. Wever CM, Geoffrion D, Grande BM, Yu S, Alcaide M, Lemaire M, Riazalhosseini Y, Hébert J, Gavino C, Vinh DC, Petrogiannis-Haliotis T, Dmitrienko S, Mann KK, Morin RD, Johnson NA. The genomic landscape of two Burkitt lymphoma cases and derived cell lines: comparison between primary and relapse samples. Leuk Lymphoma. 2018;59(9):2159-2174.
  23. Ansell SM, Minnema MC, Johnson P, Timmerman JM, Armand P, Shipp MA, Rodig SJ, Ligon AH, Roemer MGM, Reddy N, Cohen JB, Assouline S, Poon M, Sharma M, Kato K, Samakoglu S, Sumbul A, Grigg A. Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A SingleArm, Phase II Study. J Clin Oncol. 2019;37(6):481-489.
  24. Andorsky DJ, Kolibab KS, Assouline S, Forero-Torres A, Jones V, Klein LM, Patel-Donnelly D, Smith M, Ye W, Shi W, Yasenchak CA, Sharman JP. An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma. Br J Haematol. 2019;184(2):215-222.
  25. Burke JM. Shustov A, Essell J, Patel-Donnelly D, Yang J, Cen R, Ye W, Shi W, Assouline S, Sharman J. An Openlabel, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma. Clin Lymphoma Myeloma Leuk, 2018;18(8):e327-e331.
  26. Stilgenbauer S, Eichhorst B, Schetelig J, Hillmen P, Seymour JF, Coutre S, Jurczak W, Mulligan SP, Schuh A, Assouline S, Wendtner CM, Roberts AW, Davids MS, Bloehdorn J, Munir T, Böttcher S, Zhou L, Salem AH, Desai M, Chyla B, Arzt J, Kim SY, Verdugo M, Gordon G, Hallek M, Wierda WG. Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II privotal trial. J Clin Oncol. 2018;36(19):1973-1980.
  27. Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D’Rozario J, Assouline S, Owen C, Gerecitano J, Robak T, De la Serna J, Jaeger U, Cartron G, Montillo M, Humerickhouse R, Punnoose EA, Li Y, Boyer M, Humphrey K, Mobasher M, Kater AP. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. N Engl J Med. 2018;378(12):11071120.
  28. Leech AO, Vellanki SH, Rutherford EJ, Keogh A, Jahns H, Hudson L, O’Donovan N, Sabri S, Abdulkarim B, Sheehan KM, Kay EW, Young LS, Hill ADK, Smith YE, Hopkins AM. Cleavage of the extracellular domain of Junctional Adhesion Molecule-A is associated with resistance to anti-HER2 therapies in breast cancer settings. Breast Cancer Res. 2018; 20(1):140. PMID: 30458861.
  29. Traboulsi T, El Ezzy M, Dumeaux V, Audemard E, Mader S. Role of SUMOylation in differential ERα transcriptional repression by tamoxifen and fulvestrant in breast cancer cells. Oncogene. 2019;38(7):1019-1037.
  30. Xue Y, Meehan B, Macdonald E, Venneti S, Wang SX, Witkowski L, Jelinic P, Kong T, Martinez D, Morin G, Firlit M, Abedini A, Johnson R, Cencic R, Patibandla J, Chen H, Papadakis A, Auguste A, de Rink I, Kerkhoven R, Bertos N, Gotlieb W, Clarke B, Leary A, Witcher M, Guiot M, Pelletier J, Dostie J, Park M, Judkins A, Hass R, Levine D, Rak J, Vanderhyden B, Foulkes WD, Huang S. CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary. Nature Commun. 2019;10(1):558.
  31. Baloch T, López-Ozuna VM, Wang Q, Matanis E, Kessous R, Kogan L, Yasmeen A, Gotlieb WH. Sequential therapeutic targeting of ovarian cancer harboring dysfunctional BRCA1. BMC Cancer. 2019;19(1):44.
  32. Xue Y, Meehan B, Fu Z, Wang XQD, Fiset P-O, Rieker R, Levins C, Kong T, Zhu X, Morin G, Skerritt L, Herpel E, Venneti S, Martinez D, Judkins AR, Jung S, Camilleri-Broet S, Gonzalez A-V, Guiot M-C, Lockwood W, Spicer J, Agaimy A, Pastor W, Dostie J, Rak J, Foulkes WD, Huang S. SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer. Nat Commun. 2019;10(1):557. doi: 10.1038/s41467-019-08380-1.
  33. Castellsagué E, Li R, Aligue R, González S, Sanz J, Martin E, Velasco À, Capellá G, Stewart CJR, Vidal A, Majewski J, Rivera B, Polak P, Matias-Guiu X, Brunet J, Foulkes WD. Novel POLE pathogenic germline variant in a family with multiple primary tumors results in distinct mutational signatures. Hum Mutat. 2019;40(1):36-41.
  34. Larkin J, Brown MP, Arance AM, Hauschild A, Queirolo P,  Vecchio MD, Ascierto PA, Krajsova I, Schachter J, Neyns B, Garbe C, Chiarion Sileni V, Mandalà M, Gogas H, Espinosa E, Hospers G, Lorigan P,  Nyakas M, Guminski A, Liszkay G, Rutkowski P, Miller Jr WH, Donica M, Makrutzki M, Blank C.  An open-label, multicentre safety study of vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final analysis and a validated prognostic scoring system. European Journal of Cancer, 2019;107:175-185.
  35. Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, Venugopal B, Kollmannsberger C, Negrier S, Uemura M, Lee JL, Vasiliev A, Miller WH Jr, Gurney H, Berger R, Schmidinger M, Larkin J, Atkins MB, Bedke J, Wang J, Mariani M, Robbins PB, Chudnovsky A, Fowst C, Huang B, Di Pietro A and Choueiri TK. Avelumab Plus Axitinib Versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019;380(12):1103-1115.
  36. Perron M, Saragovi HU. Inhibition of CD45 Phosphatase Activity Induces Cell Cycle Arrest and Apoptosis of CD45+ Lymphoid Tumors Ex Vivo and In Vivo. Mol Pharmacol. 2018;93(6):575-580.
  37. Wang Y, Nasiri AR, Damsky WE, Perry CJ, Zhang XM, Rabin-Court A, Pollak MN, Shulman GI, Perry RJ. Uncoupling Hepatic Oxidative Phosphorylation Reduces Tumor Growth in Two Murine Models of Colon Cancer. Cell Rep 2018;24(1):47-55. PMID: 29972790.
  38. Tognon CE, Rafn B, Cetinbas NM, Kamura T, Trigo G, Rotblat B, Okumura F, Matsumoto M, Chow C, Davare M, Pollak M, Mayor T, Sorensen PH. Insulin-like growth factor 1 receptor stabilizes the ETV6-NTRK3 chimeric oncoprotein by blocking its KPC1/Rnf123mediated proteasomal degradation. J Biol Chem 2018;293(32):12502-12515. PMID: 29903916.
  39. Lord SR, Cheng WC, Liu D, Gaude E, Haider S, Metcalf T, Patel N, Teoh EJ, Gleeson F, Bradley K, Wigfield S, Zois C, McGowan DR, Ah-See ML, Thompson AM, Sharma A, Bidaut L, Pollak M, Roy PG, Karpe F, James T, English R, Adams RF, Campo L, Ayers L, Snell C, Roxanis I, Frezza C, Fenwick JD, Buffa FM, Harris AL. Integrated Pharmacodynamic Analysis Identifies Two Metabolic Adaption Pathways to Metformin in Breast Cancer. Cell Metab 2018;28(5):679-688. PMID: 30244975.
  40. Mark M, Klingbiel D, Mey U, Winterhalder R, Rothermundt C, Gillessen S, von Moos R, Pollak M, Manetsch G, Strebel R, Cathomas R. Impact of Addition of Metformin to Abiraterone in Metastatic Castration-Resistant Prostate Cancer Patients With Disease Progressing While Receiving Abiraterone Treatment (MetAb-Pro): Phase 2 Pilot Study. Clin Genitourin Cancer 2019;S1558-7673(18)30814-0. PMID: 30686756.
  41. Sharif-Askari B, Amrein L, Aloyz R, Panasci L. PARP3 inhibitors ME0328 and olaparib potentiate vinorelbine sensitization in breast cancer cell lines. Breast Cancer Res Treat. 2018;172(1):23-32.
  42. Le QC, Lefèvre T, -Gaudreault R, Laroche G et Auger M. Transdermal Diffusion, Spatial Distribution and Physical State of a Potential Anticancer Drug in Mouse Skin as Studied by Diffusion and Spectroscopic Techniques. Biomedical Spectroscopy & Imaging. 2018;7(1-2): 47-61. doi: 10.3233/BSI-180179

BCLQ 2018-2019 (8)


  1. Bisaillon R., Moison C., Thiollier C., Krosl J., Bordeleau ME., Lehnertz B., Lavallée VP., MacRae T., Mayotte N., Labelle C., Boucher G., Spinella JF., Boivin I., D’Angelo G., Lavallée S., Marinier A., Lemieux S., Hébert J., Sauvageau G. Genetic characterization of ABT-199 sensitivity in human AML. Leukemia. 2019. Accepté.
  2. Moison C, Lavallée VP, Thiollier C, Lehnertz B, Boivin I, Mayotte N, Gareau Y, Fréchette M, Blouin-Chagnon V, Corneau S, Lavallée S, Lemieux S, Marinier A, Hébert J, Sauvageau G. Complex karyotype AML displays G2/M signature and hypersensitivity to PLK1 inhibition.Blood Adv. 2019 Feb 26;3(4):552-563. doi: 10.1182/bloodadvances.2018028480. PubMed PMID: 30782614.
  3. Marquis M, Beaubois C, Lavallée VP, Abrahamowicz M, Danieli C, Lemieux S, Ahmad I, Wei A, Ting SB, Fleming S, Schwarer A, Grimwade D, Grey W, Hills RK, Vyas P, Russell N, Sauvageau G, Hébert J. High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia.Blood Cancer J. 2018 Jul 19;8(8):68. doi: 10.1038/s41408-018-0103-6. PubMed PMID: 30061630.
  4. Lavallee VP, Chagraoui J, MacRae T, Marquis M, Bonnefoy A, Krosl J, Lemieux S, Marinier A, Pabst C, Rivard GE, Hebert J, Sauvageau G. Transcriptomic landscape of acute promyelocytic leukemia reveals aberrant surface expression of the platelet aggregation agonist Podoplanin. 2018. doi: 10.1038/s41375-018-0069-1. PubMed PMID: 29550835.
  5. Laumont CM,Vincent K, Hesnard L, Audemard É, Bonneil É, Laverdure JP, Gendron P, Courcelles M, Hardy MP, Côté C, Durette C, St-Pierre C, Benhammadi M, Lanoix J, Vobecky S, Haddad E, Lemieux S, Thibault P, Perreault C. Noncoding regions are the main source of targetable tumor-specific antigens. Sci Transl Med. 2018 Dec 5;10(470). pii: eaau5516. doi: 10.1126/scitranslmed.aau5516. PubMed : PMID 30518613.

Publication : projet pédiatrique en collaboration avec la Fondation COLE

  1. Roussy M., Bilodeau M., Jouan L., Tibout P., Laramée L., Lemyre E., Cardin S., Sauvageau C., Couture F., Choblet A., Patey N., Gendron P., Duval M., Teira P., Hébert J., Wilhelm BT., Choi JK., Gruber TA., Bittencourt H., Cellot S. NUP98-BPTF gene fusion identified in primary refractory acute megakaryoblastic leukemia of infancy. Genes, chromosomes & cancer. 2018; 57(6):311-319. PubMed PMID: 29427526.

Publications : Plate-forme de cytogénétique_IRIC-HMR

  1. Vadnais C, Chen R, Fraszczak J, Yu Z, Boulais J, Pinder J, Frank D, Khandanpour C, Hebert J, Dellaire G, Cote JF, Richard S, Orthwein A, Drobetsky E, Moroy T. GFI1 facilitates efficient DNA repair by regulating PRMT1 dependent methylation of MRE11 and 53BP1. Nature communications. 2018;9(1):1418. doi: 10.1038/s41467-018-03817-5. PubMed PMID: 29651020; PubMed Central PMCID: PMC5897347.
  2. Wever CM, Geoffrion D, Grande BM, Yu S, Alcaide M, Lemaire M, Riazalhosseini Y, Hebert J, Gavino C, Vinh DC, Petrogiannis-Haliotis T, Dmitrienko S, Mann KK, Morin RD, Johnson NA. The genomic landscape of two Burkitt lymphoma cases and derived cell lines: comparison between primary and relapse samples. Leukemia & lymphoma. 2018:1-16. doi: 10.1080/10428194.2017.1413186. PubMed PMID: 29295643.

BTD– subsidized members only 2017-2018 (32)


  1. Sheta R, Bachvarova M, Plante M, Gregoire J, Renaud M-C, Sebastianelli A, Popa I, Bachvarov D. Altered expression of different GalNAc-Transferases (GalNAc-Ts) is associated with disease progression and poor prognosis in women with high-grade serous ovarian cancer. Int J Oncol. 2017; 51: 1887-1897.
  2. Sheta R, Wang Z-Q, Bachvarova M, Plante M, Gregoire J, Renaud M-C, Sebastianelli A, Gobeil S, Morin C, Macdonald E, Vanderhyden B, Bachvarov D. Hic-5 regulates epithelial to mesenchymal transition in ovarian cancer cells in a TGFβ1-independent manner. 2017;8(47): 82506-82530.
  3. Julien Daubriac,1 Shiwei Han,1 Jelena Grahovac,1 Eve Smith,1 Abdel Hosein,2 Marguerite Buchanan,2 Mark Basik,2 and Yves Boucher1. The crosstalk between breast carcinoma-associated fibroblasts and cancer cells promotes RhoA-dependent invasion via IGF-1 and PAI-1. Oncotarget. 2018 Feb 13; 9(12): 10375Ð10387.
  4. Savage P1, Blanchet-Cohen A2, Revil T3, Badescu D3, Saleh SMI4, Wang YC3, Zuo D5, Liu L5, Bertos NR5, Munoz-Ramos V5, Basik M6, Petrecca K7, Asselah J8, Meterissian S9, Guiot MC10, Omeroglu A10, Kleinman CL11, Park M12, Ragoussis J13. A Targetable EGFR-Dependent Tumor-Initiating Program in Breast Cancer. Cell Rep. 2017 Oct 31;21(5):1140-1149. doi: 10.1016/j.celrep.2017.10.015.
  5. Aguilar-Mahecha A1, Lafleur J1, Pelmus M2, Seguin C3, Lan C1, Discepola F3, Kovacina B3, Christodoulopoulos R4, Salvucci O5, Mihalcioiu C6, Roy JA7, Robidoux A8, Marcus EA9, Batist G1,10, Basik M1. The identification of challenges in tissue collection for biomarker studies: the Q-CROC-03 neoadjuvant breast cancer translational trial experience. Mod Pathol. 2017 Nov;30(11):1567-1576. doi: 10.1038/modpathol.2017.82.
  6. Alcaide M1, Yu S1, Davidson J1, Albuquerque M1, Bushell K1, Fornika D1, Arthur S1, Grande BM1, McNamara S2, Tertre MCD2, Batist G2, Huntsman DG3,4, Cavallone L5, Aguilar A5, Basik M5, Johnson NA5, Deyell RJ6, Rassekh SR6, Morin RD7. Targeted error-suppressed quantification of circulating tumor DNA using semi-degenerate barcoded adapters and biotinylated baits. Sci Rep. 2017 Sep 5;7(1):10574. doi: 10.1038/s41598-017-10269-2.
  7. Tremblay‐LeMay, R., Hogue, J. C., Provencher, L., Poirier, B., Poirier, É., Laberge, S., Diorio, C., and Desbiens, C. 2017. How Wide Should Margins Be for Phyllodes Tumors of the Breast?. The breast journal, 23(3):315-322.
  8. Ennour-Idrissi, K., Maunsell, E., and Diorio, C. 2017. Telomere length and breast cancer prognosis: a systematic review. Cancer Epidemiology, Biomarkers & Prevention, 26(1): 3-10.
  9. Bouchard-Fortier, A., Blanchette, C., Provencher, L., and Diorio, C. 2017. Prognostic and predictive value of a low estrogen receptor expression in breast cancer. Current Oncology, 24(2):e106-e114. doi:10.3747/co.24.3238.
  10. Furrer, D., Jacob, S., Caron, C., Sanschagrin, F., Provencher, L., and Diorio, C. 2017. Concordance of HER2 Immunohistochemistry and Fluorescence In Situ Hybridization Using Tissue Microarray in Breast Cancer. Anticancer Research, 37(6): 3323-3329.
  11. Abulkhir, A., Samarani, S., Amre, D., Duval, M., Haddad, E., Sinnett, D., Leclerc, JM., Diorio, C., and Ahmad, A. 2017. A protective role of IL-37 in cancer: a new hope for cancer patients. Journal of leukocyte biology, 101(2): 395-406.
  12. Yousef, E. M., Furrer, D., Laperriere, D. L., Tahir, M. R., Mader, S., Diorio, C., and Gaboury, L. A. 2017. MCM2: An alternative to Ki-67 for measuring breast cancer cell proliferation. Modern Pathology, 30(5):682-697.
  13. Brisson, J., Bérubé, S., Diorio, C., Masse, B., Lemieux, J., Duchesne, T., Delvin, E., Vieth, R., Yaffe, M., and Chiquette, J. A randomized double-blind placebo-controlled trial of the effect of vitamin D3 supplementation on breast density in premenopausal women. 2017. Cancer Epidemiology, Biomarkers & Prevention, 10.1158/1055-9965.EPI-17-0249.
  14. Hanna, M., Dumas, I., Orain, M., Jacob, S., Têtu, B., Sanschagrin, F., Bureau, A., Poirier, B., and Diorio, C. 2017. Association between Local Inflammation and Breast Tissue Age-Related Lobular Involution. Plos One, 12(8):e0183579.
  15. Hanna, M., and Diorio, C. 2017. In Reply: Association between expression of inflammatory markers in normal breast tissue and mammographic density among premenopausal and postmenopausal women. Menopause, 24(7): 865-866.
  16. Moussa, H., Guertin, M.-H., Nguile-Makao, M., Allaire, J., Robitaille, K., Pelletier, J.-F., Diorio, C., Lamarche, B., Julien, P., Morrel, X., Desmeules, P., Têtu, B., and Fradet, V. 2018. Omega-3 fatty acids and risk of prostate cancer progression during active surveillance. Sumitted to Journal of the National Cancer Institute.
  17. Baert A, Machackova E, Coene I, Cremin C, Turner K, Portigal-Todd C, Asrat MJ, Nuk J, Mindlin A, Young S, MacMillan A, Van Maerken T, Trbusek M, McKinnon W, Wood ME, Foulkes WD, Santamariña M, de la Hoya M, Foretova L, Poppe B, Vral A, Rosseel T, De Leeneer K, Vega A, Claes KBM. Thorough in silico and in vitro cDNA analysis of 21 putative BRCA1 and BRCA2 splice variants and a complex tandem duplication in BRCA2 allowing the identification of activated cryptic splice donor sites in BRCA2 exon 11. Hum Mutat. 2018 Apr;39(4):515-526. doi: 10.1002/humu.23390. Epub 2018 Jan 22. PubMed PMID: 29280214.
  18. Toland AE, Forman A, Couch FJ, Culver JO, Eccles DM, Foulkes WD, Hogervorst FBL, Houdayer C, Levy-Lahad E, Monteiro AN, Neuhausen SL, Plon SE, Sharan SK, Spurdle AB, Szabo C, Brody LC; BIC Steering Committee. Clinical testing of BRCA1 and BRCA2: a worldwide snapshot of technological practices. NPJ Genom Med. 2018 Feb 15;3:7. doi: 10.1038/s41525-018-0046-7. eCollection 2018. PubMed PMID: 29479477; PubMed Central PMCID: PMC5814433.
  19. Guedaoura S, Pelletier S, Foulkes WD, Hamet P, Simard J, Wong N, El Haffaf Z, Chiquette J, Dorval M. No evidence of excessive cancer screening in female noncarriers from BRCA1/2 mutation-positive families. Curr Oncol. 2017 Dec;24(6):352-359. doi: 10.3747/co.24.3759. Epub 2017 Dec 20. PubMed PMID: 29270046; PubMed Central PMCID: PMC5736476.
  20. Milne RL, Kuchenbaecker KB, Michailidou K, Beesley J, Kar S, Lindström S, Hui S, Lemaçon A, Soucy P, Dennis J, Jiang X, Rostamianfar A, Finucane H, Bolla MK, McGuffog L, Wang Q, Aalfs CM; ABCTB Investigators, Adams M, Adlard J, Agata S, Ahmed S, Ahsan H, Aittomäki K, Al-Ejeh F, Allen J, Ambrosone CB, Amos CI, Andrulis IL, (… 120 others …), Foulkes WD, (… 322 others …). Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nat Genet. 2017 Dec;49(12):1767-1778. doi: 10.1038/ng.3785. Epub 2017 Oct 23. PubMed PMID: 29058716; PubMed Central PMCID: PMC5808456.
  21. Narod S, Booth CM, Foulkes WD. Olaparib for Metastatic Germline BRCA-Mutated Breast Cancer. N Engl J Med. 2017 Nov 2;377(18):1792. doi: 10.1056/NEJMc1711644.  PubMed PMID: 29094857.
  22. Polak P, Kim J, Braunstein LZ, Karlic R, Haradhavala NJ, Tiao G, Rosebrock D, Livitz D, Kübler K, Mouw KW, Kamburov A, Maruvka YE, Leshchiner I, Lander ES, Golub TR, Zick A, Orthwein A, Lawrence MS, Batra RN, Caldas C, Haber DA, Laird PW, Shen H, Ellisen LW, D’Andrea AD, Chanock SJ, Foulkes WD, Getz G. A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer. Nat Genet. 2017 Oct;49(10):1476-1486. doi: 10.1038/ng.3934. Epub 2017 Aug 21. PubMed PMID: 28825726.
  23. Foo TK, Tischkowitz M, Simhadri S, Boshari T, Zayed N, Burke KA, Berman SH, Blecua P, Riaz N, Huo Y, Ding YC, Neuhausen SL, Weigelt B, Reis-Filho JS, Foulkes WD, Xia B. Compromised BRCA1-PALB2 interaction is associated with breast cancer risk. Oncogene. 2017 Jul 20;36(29):4161-4170. doi: 10.1038/onc.2017.46. Epub 2017 Mar 20. PubMed PMID: 28319063; PubMed Central PMCID: PMC5519427.
  24. McGee J, Giannakeas V, Karlan B, Lubinski J, Gronwald J, Rosen B, McLaughlin J, Risch H, Sun P, Foulkes WD, Neuhausen SL, Kotsopoulos J, Narod SA; Hereditary  Ovarian Cancer Clinical Study Group. Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted? Gynecol Oncol. 2017 May;145(2):346-351. doi: 10.1016/j.ygyno.2017.02.032. Epub 2017 Mar 14. PubMed PMID: 28314588.
  25. Krüger K, Wik E, Knutsvik G, Nalwoga H, Klingen TA, Arnes JB, Chen Y, Mannelqvist M, Dimitrakopoulou K, Stefansson IM, Birkeland E, Aas T, Tobin NP, Jonassen I, Bergh J, Foulkes WD, Akslen LA. Expression of Nestin associates with BRCA1 mutations, a basal-like phenotype and aggressive breast cancer. Sci Rep. 2017 Apr 24;7(1):1089. doi: 10.1038/s41598-017-00862-w. PubMed PMID: 28439082; PubMed Central PMCID: PMC5430803.
  26. Kogan L1, Laskov I2, Amajoud Z1, Abitbol J3, Yasmeen A4, Octeau D4, Fatnassi A3, Kessous R1, Eisenberg N5, Lau S1, Gotlieb WH6, Salvador S1. Dose dense carboplatin paclitaxel improves progression free survival in patients with endometrial cancer. Gynecol Oncol. 2017 Oct;147(1):30-35. doi: 10.1016/j.ygyno.2017.07.134. Epub 2017 Jul 20.
  27. Saleh SMI et al., “Identification of Interacting Stromal Axes in Triple-Negative Breast Cancer.” Cancer Research 77:4673-4683 (september 2017)
  28. Matte I1, Garde-Granger P2, Bessette P3, Piché A4. Ascites from ovarian cancer patients stimulates MUC16 mucin expression and secretion in human peritoneal mesothelial cells through an Akt-dependent pathway. BMC Cancer. 2019 Apr 30;19(1):406. doi: 10.1186/s12885-019-5611-7.
  29. Matte I, Bessette P, Piché A. Chapitre In Tech Open : Ascites in Ovarian Cancer Progression: Opportunities for Biomarker Discovery and New Avenues for Targeted Therapies. Nov 29 2017
  30. Kessous R, Octeau D, Klein K, Tonin PN, Greenwood CMT, Pelmus M, Laskov I, Kogan L, Salvador S, Lau S, Yasmeen A, Gotlieb WH. 2018. Distinct homologous recombination gene expression profiles after neoadjuvant chemotherapy associated with clinical outcome in patients with ovarian cancer. Gynecol Oncol. 2018 Mar;148(3):553-558.
  31. Rivera B, Di Iorio M, Frankum J, Nadaf J, Fahiminiya S, Arcand SL, Burk DL, Grapton D, Tomiak E, Hastings V, Hamel N, Wagener R, Aleynikova O, Giroux S, Hamdan FF, Dionne-Laporte A, Zogopoulos G, Rousseau F, Berghuis AM, Provencher D, Rouleau GA, Michaud JL, Mes-Masson AM, Majewski J, Bens S, Siebert R, Narod SA, Akbari MR, Lord CJ, Tonin PN, Orthwein A, Foulkes WD. 2017 Functionally Null RAD51D Missense Mutation Associates Strongly with Ovarian Carcinoma. Cancer Res. 2017 Aug 15;77(16):4517-4529. Epub 2017 Jun 23
  32. Labrie M, De Araujo LOF, Communal L, Mes-Masson AM, St-Pierre Y. Tissue and plasma levels of galectins in patients with high grade serous ovarian carcinoma as new predictive biomarkers. Sci Rep. 2017 Oct 16;7(1):13244

TE 2017-2018 (35)


  1. R Ahn, V Sabourin, AM Bolt, S Hébert, S Totten, N De Jay, MC Festa, YK Young, YK Im, T Pawson, AE Koromilas, WJ Muller, KK Mann, CL Kleinman, and J Ursini-Siegel. The Shc1 adaptor simultaneously balances Stat1 and Stat3 activity to promote breast cancer immune suppression.  Nat Commun 8:14638, 2017.
  2. MS Dahabieh, Z Ha, E Di Pietro, JN Nichol, AM Bolt, C Goncalves, D Dupéré-Richer, F Pettersson, KK Mann, NE Braverman, SV Del Rincón, WH Miller Jr. Peroxisomes protect lymphoma cells from HDAC inhibitor-mediated apoptosis. Cell Death Differ. 2017 Nov;24(11):1912-1924.
  3. CM Wever, D Geoffrion, BM Grande, S Yu, M Alcaide, M Lemaire, Y Riazalhosseini, J Hébert, C Gavino, DC Vinh, T Petrogiannis-Haliotis, S Dmitrienko, KK Mann, RD Morin, NA Johnson. The genomic landscape of two Burkitt lymphoma cases and derived cell lines: comparison between primary and relapse samples. Leuk Lymphoma. 2018 Jan 3:1-16.
  4. A Arabzadeh, K McGregor, V Breton, L Van Der Kraak, UD Akavia, CMT Greenwood, N Beauchemin (2017). EphA2 signaling is impacted by carcinoembryonic antigen cell adhesion molecule 1-L expression in colorectal cancer liver metastasis in a cell context-dependent manner. Oncotarget 8(61): 104330-104346.
  5. Jamal R, Lapointe R, Cocolakis E, Thébault P, Kazemi S, Friedmann JE, Dionne J, Cailhier JF, Bélanger K, Ayoub JP, Le H, Lambert C, El-Hajjar J, van Kempen LC, Spatz A, Miller WH Jr (2017). Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma. J Immunother Cancer 5:1, doi: 10.1186.
  6. Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos TP, Tomita A, von Tresckow B, Shipp MA, Zhang Y, Ricart AD, Balakumaran A, Moskowitz CH; KEYNOTE Phase 2 Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classical Hodgkin Lymphoma. J Clin Oncol. 2017 Jul 1;35(19):2125-2132
  7. Alcaide M, Yu S, Davidson J, Albuquerque M, Bushell K, Fornika D, Arthur S, Grande BM, McNamara S, Tertre MCD, Batist G, Huntsman DG, Cavallone L, Aguilar A, Basik M, Johnson NA, Deyell RJ, Rassekh SR, Morin RD. Targeted error-suppressed quantification of circulating tumor DNA using semi-degenerate barcoded adapters and biotinylated baits. Sci Rep. 2017 Sep 5;7(1):10574. doi: 10.1038/s41598-017-10269-2.
  8. Chang CH, Bijian K, Qiu D, Su J, Saad A, Dahabieh MS, Miller WH Jr, Alaoui-Jamali MA. Endosomal sorting and c-Cbl targeting of paxillin to autophagosomes regulate cell-matrix adhesion turnover in human breast cancer cells. Oncotarget. 8:31199-31214, 2017.
  9. Blank CU, Larkin J, Arance AM, Hauschild A, Queirolo P, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, Garbe C, Chiarion Sileni V, Mandalà M, Gogas H, Espinosa E, Hospers GAP, Miller WH Jr, Robson S, Makrutzki M, Antic V, Brown MP. Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders’ analysis. European Journal of Medicine, 79:176-184, 2017.
  10. Chia SK, Ellard SL, Mates M, Welch S, Mihalcioiu C, Miller WH Jr, Gelmon K, Lohrisch C, Kumar V, Taylor S, Hagerman L, Goodwin R, Wang T, Sakashita S, Tsao MS, Eisenhauer E, Bradbury P. A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer. Breast Cancer Research, 19(1) 54, 2017.
  11. Petrella T, Robert C, Richtig E, Miller WH Jr., Masucci GV, Walpole E, Lebbe C, Steven N, Middleton MR, Hille D, Zhou W, Ibrahim N, Cebon J. Patient-Reported Outcomes in KEYNOTE-006, a Randomized Study of Pembrolizumab Versus Ipilimumab in Patients With Advanced Melanoma. European Journal of Cancer, 86:115-124, 2017.
  12. Zhan Y, Guo J, Yang W, Goncalves C, Rzymski T, Dreas A, Żyłkiewicz E, Mikulski M, Brzózka K, Golas A, Kong Y, Ma M, Huang F, Huor B, Qianyu G, Wurzba SD, Torres J, Cai Y, Topisirovic I, Su J, Bijian K , Alaoui-Jamali MA, Huang S, Journe F, Ghanem G, Miller WH Jr, del Rincón SV. MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma. Journal of Clinical Investigation, 12(11):4179-4192, 2017.
  13. Nemunaitis J, Young A, Ejadi S, Miller Jr W, Chen LC, Nichols G, Blotner S,  Vazvaei F,  Zhi J, and Razak A.  Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, doi: 10.1007/s00280-018-3521-z. 2018.
  14. Larkin J, Minor D,  D’Angelo S,  Neyns B,  Smylie M,  Miller WH Jr,  Gutzmer R, Linette G,  Chmielowski B, Lao CD,  Lorigan P,  Grossmann K,  Hassel JC, Sznol M, Daud A,   Sosman J,  Khushalani N,  Schadendorf D, Hoeller C,  Walker D,  Kong G,  Horak C, Weber J.   Overall survival in patients with advanced melanoma who received nivolumab vs investigator’s choice chemotherapy in CheckMate 037: a randomized, controlled, open-label phase 3 trial.  Journal of Clinical Oncology, 36: 383-390, 2018.
  15. Wang PY, Li J, Walcott FL, Kang JG, Starost MF, Talagala SL, Zhuang J, Park JH, Huffstutler RD, Bryla CM, Mai PL, Pollak M, Annunziata CM, Savage SA, Fojo AT, Hwang PM. Inhibiting mitochondrial respiration prevents cancer in a mouse model of Li-Fraumeni syndrome. J Clin Invest 127(1):132-136, 2017. PMID: 27869650.
  16. Yerushalmi R, Dong B, Chapman JW, Goss PE, Pollak MN, Burnell MJ, Levine MN, Bramwell VH, Pritchard KI, Whelan TJ, Ingle JN, Shepherd LE, Parulekar WR, Han L, Ding K, Gelmon KA. Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials. Ann Oncol 28(7):1560-1568, 2017. PMID: 28379421.
  17. Klil-Drori A, Yin H, Azoulay L, Harnois M, Gratton MO, Del Corpo A, Olnery HJ, Delage R, Leneuville P, Mollica L, Busque L, Assouline S. Early switch to second-line tyrosine kinase inhibitor in chronic myeloid leukemia patients failing to achieve early molecular response. Am J Hematol 2017 Jul 3 [epub ahead of print]
  18. Kessous R, Laskov I, Abitbol J, Bitharas J, Yasmeen A, Salvador S, Lau S, Gotlieb WH. Clinical Outcome of Neoadjuvant Chemotherapy for Advanced Ovarian Cancer. Gynecol Oncol, (2017) 144: 474.
  19. Kogan L, Laskov I, Amajoud Z, Abitbol J, Yasmeen A, Octeau D, Fatnassi A, Kessous R, Eisenberg N, Lau S, Gotlieb WH, Salvador S. Dose Dense carboplatin paclitaxel improves progression free survival in patients with endometrial cancer. Gynecol Oncol. 2017 Oct;147(1):30-35.
  20. Philip CA, Laskov I, Beauchamp MC, Marques M, Amin O, Bitharas J, Kessous R, Kogan L, Baloch T, Gotlieb WH, Yasmeen A. Inhibition of PI3KAKTmTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors. BMC Cancer. 2017 Sep 8;17(1):638
  21. Simran Kaur, Zubaidah M. Ramdzan, Marie-Christine Guiot, Li Li, Lam Leduy, Dindial Ramotar, Siham Sabri, Bassam Abdulkarim, and Alain Nepveu. CUX1 Stimulates APE1 Enzymatic Activity and Increases the Resistance of Glioblastoma Cells to the Mono-Alkylating Agent, Temozolomide. Neuro-Oncology. 2017 Sep 26. PMID: 29036362
  22. Nidhi Gupta, Karen Jung, Chengsheng Wu, Abdulraheem Alshareef, Hind Alqahtani, Sambasivarao Damaraju, John Mackey, Sunita Ghosh, Siham Sabri, Bassam Abdulkarim, Gilbert Bigras, and Raymond Lai. High Myc expression and transcription activity underlies intra-tumoral heterogeneity in triple-negative breast cancer. Oncotarget, 2017 Apr
  23. Gilabert M, Chanez B, Rho YS, Giovanini M, Turrini O, Batist G, Kavan P, Raoul JL. Evaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma. Medicine (Baltimore) 2017 Apr;96(16):e6544.
  24. Aguilar-Mahecha A, Lafleur J, Pelmus M, Seguin C, Lan C, Discepola F, Kovacina B, Christodoulopoulos R, Salvucci O, Mihalcioiu C, Roy JA, Robidoux A, Marcus EA, Batist G, Basik M. The identification of challenges in tissue collection for biomarker studies: the QCROC03 neoadjuvant breast cancer translational trial experience. Mod Pathol. 2017 Jul 28.
  25. Banerji U, Dean E, Pérez-Fidalgo JA, Batist G, Bedard PL, You B, Westin SN, Kabos P, Garrett MD, Tall M, Ambrose HJ, Barrett JC, Carr TH, Cheung SA, Corcoran C, Cullberg M, Davies BR, de Bruin EC, Elvin P, Foxley A, Lawrence P, Lindemann JPO, Maudsley R, Pass M, Rowlands V, Rugman P, Schiavon G, Yates JW, Schellens JHM. A Phase 1 open-label study to identify a dosing regimen of the pan-AKT inhibitor AZD5363 for evaluation in solid tumors and in PIK3CA-mutated breast and gynecologic cancers. Clin Cancer Res. 2017 Oct 24. pii: clincanres.2260.2017.
  26. Saleh AI, Mohamed I, Mohamed AA, Abdelkader M, Yalcin HC, Aboulkassim T, Batist G, Yasmeen A, Moustafa AA. Title:Elaeagnus angustifolia Plant Extract Inhibits Angiogenesis and Downgrades Cell Invasion of Human Oral Cancer Cells via Erk1/Erk2 Inactivation.Nutrition and Cancer 2018. Feb-Mar;70(2):297-305.Epub 2018 Jan 4.
  27. Morita M, Prudent J, Basu K, Goyon V, Katsumura S, Hulea L, Peral D, Siddiqui N, Strack S, McGuirk S, St-Pierre J, Larsson O, Topisirovic I, Vali H, McBride HM, Bergeron JJ, Sonenberg N (2017) mTOR Controls Mitochondrial Dynamics and Cell Survival via MTFP1. Mol. Cell 67(6):922-935.
  28. Ha JR, Ahn R, Smith HW, Sabourin V, Hebert S, Cepeda Canedo E, Im YK, Kleinman C, Muller WJ and Ursini-Siegel J. 2018. Integration of distinct ShcA signaling complexes promotes breast tumor growth and resistance to tyrosine kinase inhibitors. Molecular Cancer Research, doi: 10.1158/1541-7786.MCR-17-0623.
  29. Rodrigues PC, Sawazaki-Calone I, Ervolino de Oliveira C, Soares Macedo CC, Dourado MR, Cervigne NK, Miguel MC, Ferreira do Carmo A, Lambert DW, Graner E, Daniela da Silva S, Alaoui-Jamali MA, Paes Leme AF, Salo TA, Coletta RD. Fascin promotes migration and invasion and is a prognostic marker for oral squamous cell carcinoma. Oncotarget. 2017;8(43):74736-74754.
  30. Kahouli I, Malhotra M, Westfall S, Alaoui-Jamali MA, Prakash S. Design and validation of an orally administrated active L. fermentum-L. acidophilus probiotic formulation using colorectal cancer Apc Min/+ mouse model. Appl Microbiol Biotechnol. 2017. Mar;101(5):1999-2019.
  31. Pathania M, De Jay N, Maestro N, Harutyunyan A, Nitarska J, Pahlavan P, Henderson S, Mikael LG, Richard-Londt A, Zhang Y, Costa JR, Hébert S, Khazaei S, Ibrahim NS, Herrero J, Riccio A, Albrecht S, Ketteler R, Brandner S, Kleinman CL*, Jabado N*, Salomoni P*. H3.3K27M cooperates with p53 loss and PDGFRA gain in mouse embryonic neural progenitor cells to induce invasive high-grade gliomas. Cancer Cell, 13;32(5):684-700.e9. (* Co-Senior authors).
  32. Salloum R, McConechy MK, Mikael LG, Nikbakht H, De Jay N, Yang X, Fuller C, Drissi R, DeWire M, Boue D, Chow L, Finlay JL, Gayden T, Karamchandani J, Hummel T, Olshefski R, Osorio D, Stevenson C, Kleinman CL, Majewski J, Fouladi M, Jabado N. Characterizing temporal genomic heterogeneity in pediatric high-grade gliomas. Acta Neuropathologica Communications, 5(1):78
  33. Bernstein V, Ellard SL, Dent SF, Tu D, Mates M, Dhesy-Thind SK, Panasci L, Gelmon KA, Salim M, Song X, Clemons M, Ksienski D, Verma S, Simmons C, Lui H, Chi K, Feilotter H, Hagerman LJ, Seymour L. A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213. Breast Cancer Res Treat. 2017 Oct13.
  34. Ghashghaei M, Paliouras M, Heravi M, Bekerat H, Trifiro M, Niazi TM, Muanza. T.Enhanced radiosensitization of enzalutamide via schedule dependent administration to androgensensitive prostate cancer cells. Prostate. 2018 Jan;78(1):64-75.
  35. GaliciaVázquez G, Smith S, Aloyz R. Del11q-positive CLL lymphocytes exhibit altered glutamine metabolism and differential response to GLS1 and glucose metabolism inhibition. Blood Cancer J. 2018 Jan 24;8(1):13. PMID: 29367649.

BCLQ 2017-2018 (13)


  1. Vadnais C, Chen R, Fraszczak J, Yu Z, Boulais J, Pinder J, Frank D, Khandanpour C, Hébert J, Dellaire G, Côté JF, Richard S, Orthwein A, Drobetsky E, Möröy T. GFI1 facilitates efficient DNA Repair by regulating PRMT1 dependent methylation of MRE11 and 53BP1. Nat Commun. 2018 Apr 12;9(1):1418. doi: 10.1038/s41467-018-03817-5.
  2. Lavallée VP, Chagraoui J, MacRae T, Marquis M, Bonnefoy A, Krosl J, Lemieux S, Marinier A, Pabst C, Rivard GE, *Hébert J, *Sauvageau G. Transcriptomic landscape of acute promyelocytic leukemia reveals aberrant surface expression of the platelet aggregation agonist Podoplanin. Leukemia. 2018 Jun;32(6):1349-1357. doi: 10.1038/s41375-018-0069-1. Epub 2018 Feb 23.*Co-corresponding authors.
  3. Roussy M., Bilodeau M., Jouan L., Tibout P., Laramée L., Lemyre E., Cardin S., Sauvageau C., Couture F., Choblet A., Patey N., Gendron P., Duval M., Teira P., Hébert J., Wilhelm BT., Choi JK., Gruber TA., Bittencourt H., Cellot S. NUP98-BPTF gene fusion identified in primary refractory acute megakaryoblastic leukemia of infancy. Genes Chromosomes Cancer 2018, Feb 10. PubMed PMID: 29427526.
  4. Brown FC, Still E, Koche RP, Yim CY, Takao S, Cifani P, Reed C, GunasekeraS, Ficarro SB, Romanienko P, Mark W, McCarthy C, de Stanchina E, Gonen M, Seshan W, Bhola P, O’Donnell C, Spitzer B, Stutzke C, Lavallée VP, Hébert J, Krivtsov AV, Melnick A, Paietta ME, Tallman MS, Letai A, Sauvageau G, Pouliot G, Levine R, Marto JA, Armstrong SA, Kentsis A. MEF2C phosphorylation is required for chemotherapy resistance in acute myeloid leukemia. Cancer Discovery 2018. Feb 5. PubMed PMID: 29431698.
  5. Wever CM, Geoffrion D, Grande BM, Yu S, Alcaide M, Lemaire M, Riazalhosseini Y, Hébert J, Gavino C, Vinh DC, Petrogiannis-Haliotis T, Dmitrienko S, Mann KK, Morin RD, Johnson NA. The genomic landscape of two Burkitt lymphoma cases and derived cell lines: comparison between primary and relapse samples. Leukemia & lymphoma. 2018 Jan 3:1-16. PubMed PMID: 29295643.
  6. Baccelli I, Krosl J, Boucher G, Boivin I, Lavallée VP, Hébert J, Lemieux S, Marinier A, Sauvageau G. A novel approach for the identification of efficient combination therapies in primary human acute myeloid leukemia specimens. Blood cancer journal. 2017;7(2):e529. PubMed PMID: 28211886.
  7. Lin HH, Hsiao CC, Pabst C, Hébert J, Schoneberg T, Hamann J. Adhesion GPCRs in Regulating Immune Responses and Inflammation. Advances in immunology. 2017;136:163-201. PubMed PMID: 28950945.
  8. Lagace K, Barabe F, Hébert J, Cellot S, Wilhelm BT. Identification of novel biomarkers for MLL-translocated acute myeloid leukemia. Experimental hematology. 2017;56:58-63. PubMed PMID: 28911906.
  9. Barabé F, Gil L, Celton M, Bergeron A, Lamontagne V, Roques E, Lagacé K, Forest A, Johnson R, Pécheux L, Simard J, Pelloux J, Bellemare-Pelletier A, Gagnon E, Hébert J, Cellot S, Wilhelm BT. Modeling human MLL-AF9 translocated acute myeloid leukemia from single donors reveals RET as a potential therapeutic target. Leukemia. 2017;31(5):1166-76. doi: 10.1038/leu.2016.302. PubMed PMID: 27780967.
  10. Simon L, Lavallée VP, Bordeleau ME, Krosl J, Baccelli I, Boucher G, Lehnertz B, Chagraoui J, MacRae T, Ruel R, Chantigny YA, Lemieux S, Marinier A, *Hébert J, *Sauvageau G. Chemogenomic landscape of RUNX1-mutated AML reveals importance of RUNX1 allele dosage in genetics and glucocorticoid sensitivity. Clinical cancer research. 2017;23(22):6969-6981. PubMed PMID: 28855357. *Co-corresponding authors.
  11. Lehnertz B, Zhang YW, Boivin I, Mayotte N, Tomellini E, Chagraoui J, Lavallée VP, Hébert J, Sauvageau G. H3K27M/I mutations promote context-dependent transformation in acute myeloid leukemia with RUNX1 alterations. Blood. 2017;130(20):2204-2214. PubMed PMID: 28855157.
  12. Zhou F, Liu Y, Rohde C, Pauli C, Gerloff D, Kohn M, Misiak D, Baumer N, Cui C, Gollner S, Oellerich T, Serve H, Garcia-Cuellar MP, Slany R, Maciejewski JP, Przychodzen B, Seliger B, Klein HU, Bartenhagen C, Berdel WE, Dugas M, Taketo MM, Farouq D, Schwartz S, Regev A, Hébert J, Sauvageau G, Pabst C, Huttelmaier S, Muller-Tidow C. AML1-ETO requires enhanced C/D box snoRNA/RNP formation to induce self-renewal and leukaemia. Nature cell biology. 2017;19(7):844-55. PubMed PMID: 28650479.
  13. Lemieux S, Sargeant T, Laperriere D, Ismail H, Boucher G, Rozendaal M, Lavallée VP, Ashton-Beaucage D, Wilhelm B, Hébert J, Hilton DJ, Mader S, Sauvageau G. MiSTIC, an integrated platform for the analysis of heterogeneity in large tumour transcriptome datasets. Nucleic acids research. 2017;45(13):e122. PubMed PMID: 28472340.

BTD– subsidized members only 2017-2018 (32)


  1. Sheta R, Bachvarova M, Plante M, Gregoire J, Renaud M-C, Sebastianelli A, Popa I, Bachvarov D. Altered expression of different GalNAc-Transferases (GalNAc-Ts) is associated with disease progression and poor prognosis in women with high-grade serous ovarian cancer. Int J Oncol. 2017; 51: 1887-1897.
  2. Sheta R, Wang Z-Q, Bachvarova M, Plante M, Gregoire J, Renaud M-C, Sebastianelli A, Gobeil S, Morin C, Macdonald E, Vanderhyden B, Bachvarov D. Hic-5 regulates epithelial to mesenchymal transition in ovarian cancer cells in a TGFβ1-independent manner. 2017;8(47): 82506-82530.
  3. Julien Daubriac,1 Shiwei Han,1 Jelena Grahovac,1 Eve Smith,1 Abdel Hosein,2 Marguerite Buchanan,2 Mark Basik,2 and Yves Boucher1. The crosstalk between breast carcinoma-associated fibroblasts and cancer cells promotes RhoA-dependent invasion via IGF-1 and PAI-1. Oncotarget. 2018 Feb 13; 9(12): 10375Ð10387.
  4. Savage P1, Blanchet-Cohen A2, Revil T3, Badescu D3, Saleh SMI4, Wang YC3, Zuo D5, Liu L5, Bertos NR5, Munoz-Ramos V5, Basik M6, Petrecca K7, Asselah J8, Meterissian S9, Guiot MC10, Omeroglu A10, Kleinman CL11, Park M12, Ragoussis J13. A Targetable EGFR-Dependent Tumor-Initiating Program in Breast Cancer. Cell Rep. 2017 Oct 31;21(5):1140-1149. doi: 10.1016/j.celrep.2017.10.015.
  5. Aguilar-Mahecha A1, Lafleur J1, Pelmus M2, Seguin C3, Lan C1, Discepola F3, Kovacina B3, Christodoulopoulos R4, Salvucci O5, Mihalcioiu C6, Roy JA7, Robidoux A8, Marcus EA9, Batist G1,10, Basik M1. The identification of challenges in tissue collection for biomarker studies: the Q-CROC-03 neoadjuvant breast cancer translational trial experience. Mod Pathol. 2017 Nov;30(11):1567-1576. doi: 10.1038/modpathol.2017.82.
  6. Alcaide M1, Yu S1, Davidson J1, Albuquerque M1, Bushell K1, Fornika D1, Arthur S1, Grande BM1, McNamara S2, Tertre MCD2, Batist G2, Huntsman DG3,4, Cavallone L5, Aguilar A5, Basik M5, Johnson NA5, Deyell RJ6, Rassekh SR6, Morin RD7. Targeted error-suppressed quantification of circulating tumor DNA using semi-degenerate barcoded adapters and biotinylated baits. Sci Rep. 2017 Sep 5;7(1):10574. doi: 10.1038/s41598-017-10269-2.
  7. Tremblay‐LeMay, R., Hogue, J. C., Provencher, L., Poirier, B., Poirier, É., Laberge, S., Diorio, C., and Desbiens, C. 2017. How Wide Should Margins Be for Phyllodes Tumors of the Breast?. The breast journal, 23(3):315-322.
  8. Ennour-Idrissi, K., Maunsell, E., and Diorio, C. 2017. Telomere length and breast cancer prognosis: a systematic review. Cancer Epidemiology, Biomarkers & Prevention, 26(1): 3-10.
  9. Bouchard-Fortier, A., Blanchette, C., Provencher, L., and Diorio, C. 2017. Prognostic and predictive value of a low estrogen receptor expression in breast cancer. Current Oncology, 24(2):e106-e114. doi:10.3747/co.24.3238.
  10. Furrer, D., Jacob, S., Caron, C., Sanschagrin, F., Provencher, L., and Diorio, C. 2017. Concordance of HER2 Immunohistochemistry and Fluorescence In Situ Hybridization Using Tissue Microarray in Breast Cancer. Anticancer Research, 37(6): 3323-3329.
  11. Abulkhir, A., Samarani, S., Amre, D., Duval, M., Haddad, E., Sinnett, D., Leclerc, JM., Diorio, C., and Ahmad, A. 2017. A protective role of IL-37 in cancer: a new hope for cancer patients. Journal of leukocyte biology, 101(2): 395-406.
  12. Yousef, E. M., Furrer, D., Laperriere, D. L., Tahir, M. R., Mader, S., Diorio, C., and Gaboury, L. A. 2017. MCM2: An alternative to Ki-67 for measuring breast cancer cell proliferation. Modern Pathology, 30(5):682-697.
  13. Brisson, J., Bérubé, S., Diorio, C., Masse, B., Lemieux, J., Duchesne, T., Delvin, E., Vieth, R., Yaffe, M., and Chiquette, J. A randomized double-blind placebo-controlled trial of the effect of vitamin D3 supplementation on breast density in premenopausal women. 2017. Cancer Epidemiology, Biomarkers & Prevention, 10.1158/1055-9965.EPI-17-0249.
  14. Hanna, M., Dumas, I., Orain, M., Jacob, S., Têtu, B., Sanschagrin, F., Bureau, A., Poirier, B., and Diorio, C. 2017. Association between Local Inflammation and Breast Tissue Age-Related Lobular Involution. Plos One, 12(8):e0183579.
  15. Hanna, M., and Diorio, C. 2017. In Reply: Association between expression of inflammatory markers in normal breast tissue and mammographic density among premenopausal and postmenopausal women. Menopause, 24(7): 865-866.
  16. Moussa, H., Guertin, M.-H., Nguile-Makao, M., Allaire, J., Robitaille, K., Pelletier, J.-F., Diorio, C., Lamarche, B., Julien, P., Morrel, X., Desmeules, P., Têtu, B., and Fradet, V. 2018. Omega-3 fatty acids and risk of prostate cancer progression during active surveillance. Sumitted to Journal of the National Cancer Institute.
  17. Baert A, Machackova E, Coene I, Cremin C, Turner K, Portigal-Todd C, Asrat MJ, Nuk J, Mindlin A, Young S, MacMillan A, Van Maerken T, Trbusek M, McKinnon W, Wood ME, Foulkes WD, Santamariña M, de la Hoya M, Foretova L, Poppe B, Vral A, Rosseel T, De Leeneer K, Vega A, Claes KBM. Thorough in silico and in vitro cDNA analysis of 21 putative BRCA1 and BRCA2 splice variants and a complex tandem duplication in BRCA2 allowing the identification of activated cryptic splice donor sites in BRCA2 exon 11. Hum Mutat. 2018 Apr;39(4):515-526. doi: 10.1002/humu.23390. Epub 2018 Jan 22. PubMed PMID: 29280214.
  18. Toland AE, Forman A, Couch FJ, Culver JO, Eccles DM, Foulkes WD, Hogervorst FBL, Houdayer C, Levy-Lahad E, Monteiro AN, Neuhausen SL, Plon SE, Sharan SK, Spurdle AB, Szabo C, Brody LC; BIC Steering Committee. Clinical testing of BRCA1 and BRCA2: a worldwide snapshot of technological practices. NPJ Genom Med. 2018 Feb 15;3:7. doi: 10.1038/s41525-018-0046-7. eCollection 2018. PubMed PMID: 29479477; PubMed Central PMCID: PMC5814433.
  19. Guedaoura S, Pelletier S, Foulkes WD, Hamet P, Simard J, Wong N, El Haffaf Z, Chiquette J, Dorval M. No evidence of excessive cancer screening in female noncarriers from BRCA1/2 mutation-positive families. Curr Oncol. 2017 Dec;24(6):352-359. doi: 10.3747/co.24.3759. Epub 2017 Dec 20. PubMed PMID: 29270046; PubMed Central PMCID: PMC5736476.
  20. Milne RL, Kuchenbaecker KB, Michailidou K, Beesley J, Kar S, Lindström S, Hui S, Lemaçon A, Soucy P, Dennis J, Jiang X, Rostamianfar A, Finucane H, Bolla MK, McGuffog L, Wang Q, Aalfs CM; ABCTB Investigators, Adams M, Adlard J, Agata S, Ahmed S, Ahsan H, Aittomäki K, Al-Ejeh F, Allen J, Ambrosone CB, Amos CI, Andrulis IL, (… 120 others …), Foulkes WD, (… 322 others …). Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nat Genet. 2017 Dec;49(12):1767-1778. doi: 10.1038/ng.3785. Epub 2017 Oct 23. PubMed PMID: 29058716; PubMed Central PMCID: PMC5808456.
  21. Narod S, Booth CM, Foulkes WD. Olaparib for Metastatic Germline BRCA-Mutated Breast Cancer. N Engl J Med. 2017 Nov 2;377(18):1792. doi: 10.1056/NEJMc1711644.  PubMed PMID: 29094857.
  22. Polak P, Kim J, Braunstein LZ, Karlic R, Haradhavala NJ, Tiao G, Rosebrock D, Livitz D, Kübler K, Mouw KW, Kamburov A, Maruvka YE, Leshchiner I, Lander ES, Golub TR, Zick A, Orthwein A, Lawrence MS, Batra RN, Caldas C, Haber DA, Laird PW, Shen H, Ellisen LW, D’Andrea AD, Chanock SJ, Foulkes WD, Getz G. A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer. Nat Genet. 2017 Oct;49(10):1476-1486. doi: 10.1038/ng.3934. Epub 2017 Aug 21. PubMed PMID: 28825726.
  23. Foo TK, Tischkowitz M, Simhadri S, Boshari T, Zayed N, Burke KA, Berman SH, Blecua P, Riaz N, Huo Y, Ding YC, Neuhausen SL, Weigelt B, Reis-Filho JS, Foulkes WD, Xia B. Compromised BRCA1-PALB2 interaction is associated with breast cancer risk. Oncogene. 2017 Jul 20;36(29):4161-4170. doi: 10.1038/onc.2017.46. Epub 2017 Mar 20. PubMed PMID: 28319063; PubMed Central PMCID: PMC5519427.
  24. McGee J, Giannakeas V, Karlan B, Lubinski J, Gronwald J, Rosen B, McLaughlin J, Risch H, Sun P, Foulkes WD, Neuhausen SL, Kotsopoulos J, Narod SA; Hereditary  Ovarian Cancer Clinical Study Group. Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted? Gynecol Oncol. 2017 May;145(2):346-351. doi: 10.1016/j.ygyno.2017.02.032. Epub 2017 Mar 14. PubMed PMID: 28314588.
  25. Krüger K, Wik E, Knutsvik G, Nalwoga H, Klingen TA, Arnes JB, Chen Y, Mannelqvist M, Dimitrakopoulou K, Stefansson IM, Birkeland E, Aas T, Tobin NP, Jonassen I, Bergh J, Foulkes WD, Akslen LA. Expression of Nestin associates with BRCA1 mutations, a basal-like phenotype and aggressive breast cancer. Sci Rep. 2017 Apr 24;7(1):1089. doi: 10.1038/s41598-017-00862-w. PubMed PMID: 28439082; PubMed Central PMCID: PMC5430803.
  26. Kogan L1, Laskov I2, Amajoud Z1, Abitbol J3, Yasmeen A4, Octeau D4, Fatnassi A3, Kessous R1, Eisenberg N5, Lau S1, Gotlieb WH6, Salvador S1. Dose dense carboplatin paclitaxel improves progression free survival in patients with endometrial cancer. Gynecol Oncol. 2017 Oct;147(1):30-35. doi: 10.1016/j.ygyno.2017.07.134. Epub 2017 Jul 20.
  27. Saleh SMI et al., “Identification of Interacting Stromal Axes in Triple-Negative Breast Cancer.” Cancer Research 77:4673-4683 (september 2017)
  28. Matte I1, Garde-Granger P2, Bessette P3, Piché A4. Ascites from ovarian cancer patients stimulates MUC16 mucin expression and secretion in human peritoneal mesothelial cells through an Akt-dependent pathway. BMC Cancer. 2019 Apr 30;19(1):406. doi: 10.1186/s12885-019-5611-7.
  29. Matte I, Bessette P, Piché A. Chapitre In Tech Open : Ascites in Ovarian Cancer Progression: Opportunities for Biomarker Discovery and New Avenues for Targeted Therapies. Nov 29 2017
  30. Kessous R, Octeau D, Klein K, Tonin PN, Greenwood CMT, Pelmus M, Laskov I, Kogan L, Salvador S, Lau S, Yasmeen A, Gotlieb WH. 2018. Distinct homologous recombination gene expression profiles after neoadjuvant chemotherapy associated with clinical outcome in patients with ovarian cancer. Gynecol Oncol. 2018 Mar;148(3):553-558.
  31. Rivera B, Di Iorio M, Frankum J, Nadaf J, Fahiminiya S, Arcand SL, Burk DL, Grapton D, Tomiak E, Hastings V, Hamel N, Wagener R, Aleynikova O, Giroux S, Hamdan FF, Dionne-Laporte A, Zogopoulos G, Rousseau F, Berghuis AM, Provencher D, Rouleau GA, Michaud JL, Mes-Masson AM, Majewski J, Bens S, Siebert R, Narod SA, Akbari MR, Lord CJ, Tonin PN, Orthwein A, Foulkes WD. 2017 Functionally Null RAD51D Missense Mutation Associates Strongly with Ovarian Carcinoma. Cancer Res. 2017 Aug 15;77(16):4517-4529. Epub 2017 Jun 23
  32. Labrie M, De Araujo LOF, Communal L, Mes-Masson AM, St-Pierre Y. Tissue and plasma levels of galectins in patients with high grade serous ovarian carcinoma as new predictive biomarkers. Sci Rep. 2017 Oct 16;7(1):13244

TE 2017-2018 (35)


  1. R Ahn, V Sabourin, AM Bolt, S Hébert, S Totten, N De Jay, MC Festa, YK Young, YK Im, T Pawson, AE Koromilas, WJ Muller, KK Mann, CL Kleinman, and J Ursini-Siegel. The Shc1 adaptor simultaneously balances Stat1 and Stat3 activity to promote breast cancer immune suppression.  Nat Commun 8:14638, 2017.
  2. MS Dahabieh, Z Ha, E Di Pietro, JN Nichol, AM Bolt, C Goncalves, D Dupéré-Richer, F Pettersson, KK Mann, NE Braverman, SV Del Rincón, WH Miller Jr. Peroxisomes protect lymphoma cells from HDAC inhibitor-mediated apoptosis. Cell Death Differ. 2017 Nov;24(11):1912-1924.
  3. CM Wever, D Geoffrion, BM Grande, S Yu, M Alcaide, M Lemaire, Y Riazalhosseini, J Hébert, C Gavino, DC Vinh, T Petrogiannis-Haliotis, S Dmitrienko, KK Mann, RD Morin, NA Johnson. The genomic landscape of two Burkitt lymphoma cases and derived cell lines: comparison between primary and relapse samples. Leuk Lymphoma. 2018 Jan 3:1-16.
  4. A Arabzadeh, K McGregor, V Breton, L Van Der Kraak, UD Akavia, CMT Greenwood, N Beauchemin (2017). EphA2 signaling is impacted by carcinoembryonic antigen cell adhesion molecule 1-L expression in colorectal cancer liver metastasis in a cell context-dependent manner. Oncotarget 8(61): 104330-104346.
  5. Jamal R, Lapointe R, Cocolakis E, Thébault P, Kazemi S, Friedmann JE, Dionne J, Cailhier JF, Bélanger K, Ayoub JP, Le H, Lambert C, El-Hajjar J, van Kempen LC, Spatz A, Miller WH Jr (2017). Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma. J Immunother Cancer 5:1, doi: 10.1186.
  6. Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos TP, Tomita A, von Tresckow B, Shipp MA, Zhang Y, Ricart AD, Balakumaran A, Moskowitz CH; KEYNOTE Phase 2 Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classical Hodgkin Lymphoma. J Clin Oncol. 2017 Jul 1;35(19):2125-2132
  7. Alcaide M, Yu S, Davidson J, Albuquerque M, Bushell K, Fornika D, Arthur S, Grande BM, McNamara S, Tertre MCD, Batist G, Huntsman DG, Cavallone L, Aguilar A, Basik M, Johnson NA, Deyell RJ, Rassekh SR, Morin RD. Targeted error-suppressed quantification of circulating tumor DNA using semi-degenerate barcoded adapters and biotinylated baits. Sci Rep. 2017 Sep 5;7(1):10574. doi: 10.1038/s41598-017-10269-2.
  8. Chang CH, Bijian K, Qiu D, Su J, Saad A, Dahabieh MS, Miller WH Jr, Alaoui-Jamali MA. Endosomal sorting and c-Cbl targeting of paxillin to autophagosomes regulate cell-matrix adhesion turnover in human breast cancer cells. Oncotarget. 8:31199-31214, 2017.
  9. Blank CU, Larkin J, Arance AM, Hauschild A, Queirolo P, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, Garbe C, Chiarion Sileni V, Mandalà M, Gogas H, Espinosa E, Hospers GAP, Miller WH Jr, Robson S, Makrutzki M, Antic V, Brown MP. Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders’ analysis. European Journal of Medicine, 79:176-184, 2017.
  10. Chia SK, Ellard SL, Mates M, Welch S, Mihalcioiu C, Miller WH Jr, Gelmon K, Lohrisch C, Kumar V, Taylor S, Hagerman L, Goodwin R, Wang T, Sakashita S, Tsao MS, Eisenhauer E, Bradbury P. A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer. Breast Cancer Research, 19(1) 54, 2017.
  11. Petrella T, Robert C, Richtig E, Miller WH Jr., Masucci GV, Walpole E, Lebbe C, Steven N, Middleton MR, Hille D, Zhou W, Ibrahim N, Cebon J. Patient-Reported Outcomes in KEYNOTE-006, a Randomized Study of Pembrolizumab Versus Ipilimumab in Patients With Advanced Melanoma. European Journal of Cancer, 86:115-124, 2017.
  12. Zhan Y, Guo J, Yang W, Goncalves C, Rzymski T, Dreas A, Żyłkiewicz E, Mikulski M, Brzózka K, Golas A, Kong Y, Ma M, Huang F, Huor B, Qianyu G, Wurzba SD, Torres J, Cai Y, Topisirovic I, Su J, Bijian K , Alaoui-Jamali MA, Huang S, Journe F, Ghanem G, Miller WH Jr, del Rincón SV. MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma. Journal of Clinical Investigation, 12(11):4179-4192, 2017.
  13. Nemunaitis J, Young A, Ejadi S, Miller Jr W, Chen LC, Nichols G, Blotner S,  Vazvaei F,  Zhi J, and Razak A.  Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, doi: 10.1007/s00280-018-3521-z. 2018.
  14. Larkin J, Minor D,  D’Angelo S,  Neyns B,  Smylie M,  Miller WH Jr,  Gutzmer R, Linette G,  Chmielowski B, Lao CD,  Lorigan P,  Grossmann K,  Hassel JC, Sznol M, Daud A,   Sosman J,  Khushalani N,  Schadendorf D, Hoeller C,  Walker D,  Kong G,  Horak C, Weber J.   Overall survival in patients with advanced melanoma who received nivolumab vs investigator’s choice chemotherapy in CheckMate 037: a randomized, controlled, open-label phase 3 trial.  Journal of Clinical Oncology, 36: 383-390, 2018.
  15. Wang PY, Li J, Walcott FL, Kang JG, Starost MF, Talagala SL, Zhuang J, Park JH, Huffstutler RD, Bryla CM, Mai PL, Pollak M, Annunziata CM, Savage SA, Fojo AT, Hwang PM. Inhibiting mitochondrial respiration prevents cancer in a mouse model of Li-Fraumeni syndrome. J Clin Invest 127(1):132-136, 2017. PMID: 27869650.
  16. Yerushalmi R, Dong B, Chapman JW, Goss PE, Pollak MN, Burnell MJ, Levine MN, Bramwell VH, Pritchard KI, Whelan TJ, Ingle JN, Shepherd LE, Parulekar WR, Han L, Ding K, Gelmon KA. Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials. Ann Oncol 28(7):1560-1568, 2017. PMID: 28379421.
  17. Klil-Drori A, Yin H, Azoulay L, Harnois M, Gratton MO, Del Corpo A, Olnery HJ, Delage R, Leneuville P, Mollica L, Busque L, Assouline S. Early switch to second-line tyrosine kinase inhibitor in chronic myeloid leukemia patients failing to achieve early molecular response. Am J Hematol 2017 Jul 3 [epub ahead of print]
  18. Kessous R, Laskov I, Abitbol J, Bitharas J, Yasmeen A, Salvador S, Lau S, Gotlieb WH. Clinical Outcome of Neoadjuvant Chemotherapy for Advanced Ovarian Cancer. Gynecol Oncol, (2017) 144: 474.
  19. Kogan L, Laskov I, Amajoud Z, Abitbol J, Yasmeen A, Octeau D, Fatnassi A, Kessous R, Eisenberg N, Lau S, Gotlieb WH, Salvador S. Dose Dense carboplatin paclitaxel improves progression free survival in patients with endometrial cancer. Gynecol Oncol. 2017 Oct;147(1):30-35.
  20. Philip CA, Laskov I, Beauchamp MC, Marques M, Amin O, Bitharas J, Kessous R, Kogan L, Baloch T, Gotlieb WH, Yasmeen A. Inhibition of PI3KAKTmTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors. BMC Cancer. 2017 Sep 8;17(1):638
  21. Simran Kaur, Zubaidah M. Ramdzan, Marie-Christine Guiot, Li Li, Lam Leduy, Dindial Ramotar, Siham Sabri, Bassam Abdulkarim, and Alain Nepveu. CUX1 Stimulates APE1 Enzymatic Activity and Increases the Resistance of Glioblastoma Cells to the Mono-Alkylating Agent, Temozolomide. Neuro-Oncology. 2017 Sep 26. PMID: 29036362
  22. Nidhi Gupta, Karen Jung, Chengsheng Wu, Abdulraheem Alshareef, Hind Alqahtani, Sambasivarao Damaraju, John Mackey, Sunita Ghosh, Siham Sabri, Bassam Abdulkarim, Gilbert Bigras, and Raymond Lai. High Myc expression and transcription activity underlies intra-tumoral heterogeneity in triple-negative breast cancer. Oncotarget, 2017 Apr
  23. Gilabert M, Chanez B, Rho YS, Giovanini M, Turrini O, Batist G, Kavan P, Raoul JL. Evaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma. Medicine (Baltimore) 2017 Apr;96(16):e6544.
  24. Aguilar-Mahecha A, Lafleur J, Pelmus M, Seguin C, Lan C, Discepola F, Kovacina B, Christodoulopoulos R, Salvucci O, Mihalcioiu C, Roy JA, Robidoux A, Marcus EA, Batist G, Basik M. The identification of challenges in tissue collection for biomarker studies: the QCROC03 neoadjuvant breast cancer translational trial experience. Mod Pathol. 2017 Jul 28.
  25. Banerji U, Dean E, Pérez-Fidalgo JA, Batist G, Bedard PL, You B, Westin SN, Kabos P, Garrett MD, Tall M, Ambrose HJ, Barrett JC, Carr TH, Cheung SA, Corcoran C, Cullberg M, Davies BR, de Bruin EC, Elvin P, Foxley A, Lawrence P, Lindemann JPO, Maudsley R, Pass M, Rowlands V, Rugman P, Schiavon G, Yates JW, Schellens JHM. A Phase 1 open-label study to identify a dosing regimen of the pan-AKT inhibitor AZD5363 for evaluation in solid tumors and in PIK3CA-mutated breast and gynecologic cancers. Clin Cancer Res. 2017 Oct 24. pii: clincanres.2260.2017.
  26. Saleh AI, Mohamed I, Mohamed AA, Abdelkader M, Yalcin HC, Aboulkassim T, Batist G, Yasmeen A, Moustafa AA. Title:Elaeagnus angustifolia Plant Extract Inhibits Angiogenesis and Downgrades Cell Invasion of Human Oral Cancer Cells via Erk1/Erk2 Inactivation.Nutrition and Cancer 2018. Feb-Mar;70(2):297-305.Epub 2018 Jan 4.
  27. Morita M, Prudent J, Basu K, Goyon V, Katsumura S, Hulea L, Peral D, Siddiqui N, Strack S, McGuirk S, St-Pierre J, Larsson O, Topisirovic I, Vali H, McBride HM, Bergeron JJ, Sonenberg N (2017) mTOR Controls Mitochondrial Dynamics and Cell Survival via MTFP1. Mol. Cell 67(6):922-935.
  28. Ha JR, Ahn R, Smith HW, Sabourin V, Hebert S, Cepeda Canedo E, Im YK, Kleinman C, Muller WJ and Ursini-Siegel J. 2018. Integration of distinct ShcA signaling complexes promotes breast tumor growth and resistance to tyrosine kinase inhibitors. Molecular Cancer Research, doi: 10.1158/1541-7786.MCR-17-0623.
  29. Rodrigues PC, Sawazaki-Calone I, Ervolino de Oliveira C, Soares Macedo CC, Dourado MR, Cervigne NK, Miguel MC, Ferreira do Carmo A, Lambert DW, Graner E, Daniela da Silva S, Alaoui-Jamali MA, Paes Leme AF, Salo TA, Coletta RD. Fascin promotes migration and invasion and is a prognostic marker for oral squamous cell carcinoma. Oncotarget. 2017;8(43):74736-74754.
  30. Kahouli I, Malhotra M, Westfall S, Alaoui-Jamali MA, Prakash S. Design and validation of an orally administrated active L. fermentum-L. acidophilus probiotic formulation using colorectal cancer Apc Min/+ mouse model. Appl Microbiol Biotechnol. 2017. Mar;101(5):1999-2019.
  31. Pathania M, De Jay N, Maestro N, Harutyunyan A, Nitarska J, Pahlavan P, Henderson S, Mikael LG, Richard-Londt A, Zhang Y, Costa JR, Hébert S, Khazaei S, Ibrahim NS, Herrero J, Riccio A, Albrecht S, Ketteler R, Brandner S, Kleinman CL*, Jabado N*, Salomoni P*. H3.3K27M cooperates with p53 loss and PDGFRA gain in mouse embryonic neural progenitor cells to induce invasive high-grade gliomas. Cancer Cell, 13;32(5):684-700.e9. (* Co-Senior authors).
  32. Salloum R, McConechy MK, Mikael LG, Nikbakht H, De Jay N, Yang X, Fuller C, Drissi R, DeWire M, Boue D, Chow L, Finlay JL, Gayden T, Karamchandani J, Hummel T, Olshefski R, Osorio D, Stevenson C, Kleinman CL, Majewski J, Fouladi M, Jabado N. Characterizing temporal genomic heterogeneity in pediatric high-grade gliomas. Acta Neuropathologica Communications, 5(1):78
  33. Bernstein V, Ellard SL, Dent SF, Tu D, Mates M, Dhesy-Thind SK, Panasci L, Gelmon KA, Salim M, Song X, Clemons M, Ksienski D, Verma S, Simmons C, Lui H, Chi K, Feilotter H, Hagerman LJ, Seymour L. A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213. Breast Cancer Res Treat. 2017 Oct13.
  34. Ghashghaei M, Paliouras M, Heravi M, Bekerat H, Trifiro M, Niazi TM, Muanza. T.Enhanced radiosensitization of enzalutamide via schedule dependent administration to androgensensitive prostate cancer cells. Prostate. 2018 Jan;78(1):64-75.
  35. GaliciaVázquez G, Smith S, Aloyz R. Del11q-positive CLL lymphocytes exhibit altered glutamine metabolism and differential response to GLS1 and glucose metabolism inhibition. Blood Cancer J. 2018 Jan 24;8(1):13. PMID: 29367649.

BCLQ 2017-2018 (13)


  1. Vadnais C, Chen R, Fraszczak J, Yu Z, Boulais J, Pinder J, Frank D, Khandanpour C, Hébert J, Dellaire G, Côté JF, Richard S, Orthwein A, Drobetsky E, Möröy T. GFI1 facilitates efficient DNA Repair by regulating PRMT1 dependent methylation of MRE11 and 53BP1. Nat Commun. 2018 Apr 12;9(1):1418. doi: 10.1038/s41467-018-03817-5.
  2. Lavallée VP, Chagraoui J, MacRae T, Marquis M, Bonnefoy A, Krosl J, Lemieux S, Marinier A, Pabst C, Rivard GE, *Hébert J, *Sauvageau G. Transcriptomic landscape of acute promyelocytic leukemia reveals aberrant surface expression of the platelet aggregation agonist Podoplanin. Leukemia. 2018 Jun;32(6):1349-1357. doi: 10.1038/s41375-018-0069-1. Epub 2018 Feb 23.*Co-corresponding authors.
  3. Roussy M., Bilodeau M., Jouan L., Tibout P., Laramée L., Lemyre E., Cardin S., Sauvageau C., Couture F., Choblet A., Patey N., Gendron P., Duval M., Teira P., Hébert J., Wilhelm BT., Choi JK., Gruber TA., Bittencourt H., Cellot S. NUP98-BPTF gene fusion identified in primary refractory acute megakaryoblastic leukemia of infancy. Genes Chromosomes Cancer 2018, Feb 10. PubMed PMID: 29427526.
  4. Brown FC, Still E, Koche RP, Yim CY, Takao S, Cifani P, Reed C, GunasekeraS, Ficarro SB, Romanienko P, Mark W, McCarthy C, de Stanchina E, Gonen M, Seshan W, Bhola P, O’Donnell C, Spitzer B, Stutzke C, Lavallée VP, Hébert J, Krivtsov AV, Melnick A, Paietta ME, Tallman MS, Letai A, Sauvageau G, Pouliot G, Levine R, Marto JA, Armstrong SA, Kentsis A. MEF2C phosphorylation is required for chemotherapy resistance in acute myeloid leukemia. Cancer Discovery 2018. Feb 5. PubMed PMID: 29431698.
  5. Wever CM, Geoffrion D, Grande BM, Yu S, Alcaide M, Lemaire M, Riazalhosseini Y, Hébert J, Gavino C, Vinh DC, Petrogiannis-Haliotis T, Dmitrienko S, Mann KK, Morin RD, Johnson NA. The genomic landscape of two Burkitt lymphoma cases and derived cell lines: comparison between primary and relapse samples. Leukemia & lymphoma. 2018 Jan 3:1-16. PubMed PMID: 29295643.
  6. Baccelli I, Krosl J, Boucher G, Boivin I, Lavallée VP, Hébert J, Lemieux S, Marinier A, Sauvageau G. A novel approach for the identification of efficient combination therapies in primary human acute myeloid leukemia specimens. Blood cancer journal. 2017;7(2):e529. PubMed PMID: 28211886.
  7. Lin HH, Hsiao CC, Pabst C, Hébert J, Schoneberg T, Hamann J. Adhesion GPCRs in Regulating Immune Responses and Inflammation. Advances in immunology. 2017;136:163-201. PubMed PMID: 28950945.
  8. Lagace K, Barabe F, Hébert J, Cellot S, Wilhelm BT. Identification of novel biomarkers for MLL-translocated acute myeloid leukemia. Experimental hematology. 2017;56:58-63. PubMed PMID: 28911906.
  9. Barabé F, Gil L, Celton M, Bergeron A, Lamontagne V, Roques E, Lagacé K, Forest A, Johnson R, Pécheux L, Simard J, Pelloux J, Bellemare-Pelletier A, Gagnon E, Hébert J, Cellot S, Wilhelm BT. Modeling human MLL-AF9 translocated acute myeloid leukemia from single donors reveals RET as a potential therapeutic target. Leukemia. 2017;31(5):1166-76. doi: 10.1038/leu.2016.302. PubMed PMID: 27780967.
  10. Simon L, Lavallée VP, Bordeleau ME, Krosl J, Baccelli I, Boucher G, Lehnertz B, Chagraoui J, MacRae T, Ruel R, Chantigny YA, Lemieux S, Marinier A, *Hébert J, *Sauvageau G. Chemogenomic landscape of RUNX1-mutated AML reveals importance of RUNX1 allele dosage in genetics and glucocorticoid sensitivity. Clinical cancer research. 2017;23(22):6969-6981. PubMed PMID: 28855357. *Co-corresponding authors.
  11. Lehnertz B, Zhang YW, Boivin I, Mayotte N, Tomellini E, Chagraoui J, Lavallée VP, Hébert J, Sauvageau G. H3K27M/I mutations promote context-dependent transformation in acute myeloid leukemia with RUNX1 alterations. Blood. 2017;130(20):2204-2214. PubMed PMID: 28855157.
  12. Zhou F, Liu Y, Rohde C, Pauli C, Gerloff D, Kohn M, Misiak D, Baumer N, Cui C, Gollner S, Oellerich T, Serve H, Garcia-Cuellar MP, Slany R, Maciejewski JP, Przychodzen B, Seliger B, Klein HU, Bartenhagen C, Berdel WE, Dugas M, Taketo MM, Farouq D, Schwartz S, Regev A, Hébert J, Sauvageau G, Pabst C, Huttelmaier S, Muller-Tidow C. AML1-ETO requires enhanced C/D box snoRNA/RNP formation to induce self-renewal and leukaemia. Nature cell biology. 2017;19(7):844-55. PubMed PMID: 28650479.
  13. Lemieux S, Sargeant T, Laperriere D, Ismail H, Boucher G, Rozendaal M, Lavallée VP, Ashton-Beaucage D, Wilhelm B, Hébert J, Hilton DJ, Mader S, Sauvageau G. MiSTIC, an integrated platform for the analysis of heterogeneity in large tumour transcriptome datasets. Nucleic acids research. 2017;45(13):e122. PubMed PMID: 28472340.